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Abstract 
Cardiac mortality and morbidity is a significant problem in the renal failure 
population.  For some, their renal dysfunction is a consequence of their cardiac 
failure or general vascular disease; for others it develops and progresses over 
the course of their renal disease.   
Uraemic Cardiomyopathy is a group of particular cardiac abnormalities 
that are found in renal failure; left ventricular hypertrophy, ventricular dilatation 
and left ventricular systolic dysfunction.  Left ventricular hypertrophy is the 
commonest of these and occurs in 75% of those starting dialysis.  Pathological 
examination of these hearts reveals prominent cardiac fibrosis and expansion of 
the ventricular muscular wall. 
Uraemic cardiomyopathy is more common as renal function deteriorates 
but doesn’t occur in all patients requiring renal replacement therapy.  Therefore it 
has been proposed that factors other than uraemia and uraemic toxins probably 
contribute to this pathological process. 
The renin-angiotensin-aldosterone system is one of the possible 
contributing factors.  Animal studies and more recently clinical studies have 
added weight to this theory. Brilla and Weber published a set of landmark papers 
in 1992, demonstrating an increase in cardiac fibrosis in rats treated with an 
aldosterone infusion.  However, these finding were only present in rats fed a high 
sodium diet.  They also appear to be independent of hypertension; another 
known cause of left ventricular hypertrophy.    
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Evidence in humans is more difficult to prove and remains varied in 
outcome.  A recent study in a hypertensive population found a positive 
correlation between aldosterone serum levels and left ventricular mass. Evidence 
in renal failure is even more limited and it is this situation that we have focused 
on in our study. 
Transforming growth factor beta is a proposed down-stream signalling 
molecule of the renin-angiotensin-aldosterone system in cardiac fibrosis/left 
ventricular hypertrophy.  However this is not the only signalling pathway that is 
under investigation and at present the evidence is equivocal. 
This Thesis incorporates three separate but related studies. The West of 
Scotland Kidney Disease Study was a 10 year follow-up analysis of patients 
initially enrolled in 2005, with a range of renal failure from mild to end-stage, 
those on dialysis and transplanted patients.  As expected survival decreased as 
renal function declined and survival rates were better in the transplanted group 
than those on dialysis.  However, survival rates in this group of patients were not 
determined by aldosterone, total renin, aldosterone:renin ratio, left ventricular 
mass or ejection fraction.  Our study did confirm previous evidence that urinary 
protein excretion greater than 1 g/day was associated with a significant increase 
in mortality over the 10 year follow-up. 
The Aldosterone Study, aimed to identify factors affecting left ventricular 
mass and aldosterone levels in a renal failure population.  Unfortunately no link 
was identified between aldosterone and left ventricular mass, or surrogate    
  20 
markers of cardiac disease.  Also no significant factors affecting the aldosterone 
levels of these patients were identified. 
The Rat Slice Study was an experimental model developed in an attempt 
to replicate ventricular cell interactions and structure that occurs within the body. 
Rat ventricle tissue slices were used and incubated in media for 48hours. The 
media was supplemented with different concentrations of aldosterone, water or 
both to determine the effects of aldosterone and sodium concentration on TGF-β1 
production and cardiac fibrosis.  
Viability of the slices was evident at 48hours although at a much lower 
level than at the start of the experiment.  No increase in cardiac fibrosis or TGF-
β1 production was found in any of the groups of tissue slices. 
In Conclusion, the three studies undertaken found no definitive evidence 
for the role of aldosterone or TGF-β1 in cardiac fibrosis/left ventricular 
hypertrophy.  This was true of both the uraemic and non-uraemic states. 
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Chapter 1:   Introduction 
1.1    Cardiovascular Disease in Renal Failure 
1.1.1   Epidemiology and Cardiovascular Risk 
 
End stage renal failure carries an increased risk of premature death (from 
any cause) compared to the general population.  However, it is the increased risk 
of cardiovascular death that is the most pronounced; up to 100 times that of the 
general population by the time end stage renal failure is reached
 [1, 2].  This 
equates to a risk of cardiac death that is 20 times that of progression to renal 
replacement therapy 
[1].  
Recently the UK renal registry calculated the prevalence of patients 
needing renal replacement therapy as 725 per million population 
[3]. Unfortunately 
the incidence and prevalence of chronic kidney disease is not so easily defined.  
Not all patients are aware that they have renal impairment and most are followed 
up solely in the community.  Despite this, renal dysfunction, and it’s associated 
cardiovascular morbidity and mortality provide a major target group for research 
and intervention. 
1.2    Risk Factors for Cardiovascular Disease 
1.2.1  Traditional Risk Factors 
Determination of the exact cause of increased cardiovascular risk in renal 
patients is difficult to determine. Renal failure often co-exists with “traditional” risk    
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factors for cardiovascular disease, for example hypertension, diabetes and 
hyperlipidaemia. However, these “traditional” risk factors appear to have their 
effects reversed or altered in renal failure e.g. the “U-shaped curve” effect for 
blood pressure on mortality risk and the lack of evidence for statins in this 
population 
[4, 5].   
1.2.2    Non-Traditional Risk Factors 
Non-traditional risk factors include anaemia, volume overload, raised C-
reactive protein (CRP) and increased calcium/phosphate 
[1].  Despite progressive 
renal failure causing or being associated with many of the risk factors mentioned 
above, chronic renal failure itself is independently associated with increased 
cardiovascular risk 
[6].  The mechanisms for this are not yet clearly defined but 
the paragraphs below detail some of the advances and possible mechanisms 
involved. 
 
1.3   Types of Cardiac Disease in Renal Failure 
1.3.1    Atherosclerotic 
As would be expected for a population with a high proportion of traditional 
risk factors; atherosclerosis is common.  Data from the HEMO study in 2000 
demonstrated that 40% of enrolled chronic haemodialysis patients had evidence 
of coronary heart disease; patients with known unstable angina and severe heart 
failure were excluded 
[7].     
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Recent evidence suggests that the atheromatous plaques developing in 
uraemic patients are highly calcified compared with age matched controls 
[8]. 
Other non-traditional risk factors have been assessed to identify uraemia specific 
conditions necessary for this calcification and increased disease prevalence e.g. 
phosphate and CRP.    
1.3.2  Uraemic Cardiomyopathy 
Uraemic cardiomyopathy is a term that amalgamates the common cardiac 
abnormalities found in renal failure patients; left ventricular hypertrophy, left 
ventricular systolic dysfunction and left ventricular dilatation. 
Left ventricular hypertrophy (LVH) has been identified in approximately 
75% of patients reaching dialysis 
[9] and is considered an independent risk factor 
for cardiovascular mortality 
[10] [11]. 
Therefore, there has been a large emphasis in renal and cardiac research 
aimed at determining the causative factors and potential interventions to reverse 
this pathological process.  Systolic blood pressure is known to be one of the 
determinants of left ventricular mass 
[12] and has been shown in many studies to 
regress with antihypertensive treatment 
[13, 14]. However, LVH has also been 
shown in some animal and human models to develop independently of blood 
pressure 
[15, 16]. 
1.3.3  Sudden Cardiac Death 
Sudden cardiac death is the most common cause of death in end-stage 
renal failure patients and forms 62% of all cardiac deaths in this group 
[17].  It is    
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thought that these patients develop fatal cardiac arrhythmia e.g. ventricular 
tachycardia or fibrillation.  However, our knowledge of the exact 
pathological/biochemical processes underlying the final event is incomplete.  
Several theories exist to explain the high levels of sudden cardiac death in 
dialysis patients.  These include existing myocardial damage predisposing to an 
increased risk of myocardial ischaemia, rapid electrolyte shifts during dialysis, 
and coronary heart disease.  Other potential factors include chronic anaemia, 
disturbance of calcium/phosphate equilibrium, chronic fluid overload and 
inflammation i.e. high CRP 
[17]. 
Some of the most convincing evidence that coronary artery disease isn’t 
the only contributing factor comes from the evidence that coronary artery stenting 
and coronary artery bypass grafting in patients with significant stenoses did not 
prevent sudden cardiac death 
[18].   
The fact that most dialysis patients have evidence of at least one form of 
uraemic cardiomyopathy is probably one of the reasons why they are at such 
high risk of sudden cardiac death.     
   
1.4   Aldosterone 
Aldosterone (Figure 1.1a) is the primary mineralocorticoid hormone in 
humans; defined as a hormone that “promotes unidirectional transepithelial 
sodium transport” 
[19].  
It was first discovered by Sylvia Simpson and Graham Tait in adrenal 
extract and the term aldosterone was coined in 1954 
[19]. Following this    
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discovery, Jerome Conn went on to describe Conn’s syndrome linking 
aldosterone secreting tumours with hypertension and hypokalaemia 
[20].  Since 
then interest in this hormone has grown particularly in terms of its effects on 
blood pressure and the cardiovascular system. These effects will be discussed in 
more detail, later on in this chapter. 
1.4.1  The Adrenal Glands 
Aldosterone is produced in the adrenal glands; two small endocrine glands 
that lie superior and adjacent to both kidneys.  Each adrenal gland is divided 
histologically into the adrenal cortex and medulla. The cortex is then sub-divided 
into three zones; the outermost zona glomerulosa, beneath which lies the 
fasciculata and then the reticularis.  (Figure 1.2) The adrenal medulla forms the 
core of the adrenal gland and produces catecholamines rather than steroid 
hormones.  
Aldosterone is produced in relatively small amounts (10-150µg/day) 
[21] 
exclusively by the zona glomerulosa . Whereas, the zona fasciculata is 
concerned primarily with the synthesis of cortisol (10 - 20mg/day) 
[21] and the 
zona reticularis with androgens called Dehydroepiandrosterone sulphates 
(DHEAs).    
1.4.2  Synthesis 
Aldosterone and the other adrenal steroid hormones share the first part of 
their biosynthetic pathway and have a similar basic chemical structure (figure 
1.1a and 1.1b).    
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Figure 1.1a    Aldosterone 
[22]        Figure 1.1b           Cortisol 
[23] 
 
 
 
Figure 1.2   The Adrenal Gland Anatomy and Hormone 
Production 
[24] 
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The first step in this pathway is cholesterol. This is taken up from the 
blood (where it is bound to low-density lipoproteins) by a protein called 
steroidogenic acute regulatory protein (StAR). StAR allows transport of 
cholesterol into mitochondria where it is converted to pregnenolone by 
cytochrome p450 side-chain cleavage enzyme (p450scc), located on the inner 
mitochondrial membrane.  The pregnenolone is then transported into the cytosol 
where it is converted to progesterone by 3β-hydroxysteroid dehydrogenase 2 on 
the membrane of the endoplasmic reticulum.  Progesterone is then converted to 
deoxycorticosterone (DOC) by 21-hydroxylase enzyme also located in the 
endoplasmic reticulum 
[25]. (Figure1.3) 
However, differentiation of the final hormone produced by the different 
zones of the cortex is determined by the expression of specific enzymes present 
at the end of the biosynthesis pathway. The zona glomerulosa uniquely contains 
an enzyme called aldosterone synthase, present on the inner mitochondrial 
membrane. This converts DOC via 3 steps of hydroxylation (one of which is 11β- 
hydroxylation) and oxidation to aldosterone 
[26]. In contrast, in the zona 
fasciculate, progesterone is 17α-hydroxylated to deoxycortisol before being 
hydroxlated by 11β- hydroxylase enzyme to cortisol.  A small amount of 
corticosterone is also produced in the zona fasciculate from DOC by the 11β- 
hydroxylase enzyme. 
  Aldosterone synthase is present in the zona glomerulosa because of the 
local presence of the gene CYP11B2.  This is not present in the zona fasciculata;    
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instead CYP11B1 is present leading to the production of 11β- hydroxylase 
enzyme. 
 
1.5   Control of Aldosterone Production and Release 
1.5.1    ACTH 
ACTH is the pituitary hormone primarily responsible for glucocorticoid 
release and as such is known to regulate CYP11B1 expression.  However it has 
also been shown to affect aldosterone synthesis and expression of CYP11B2, 
athough the mechanism remains unclear.   
ACTH’s effects on aldosterone release can be separated into two parts. 
Acutely, ACTH increases aldosterone release via an increase in the 
Steroidogenic acute regulatory (STAR) protein 
[27].  This enables more 
cholesterol to be taken into the mitochondria in order to start the process of 
steroidogenesis.   
However chronic infusion and 24 – 48 hours post acute administration 
causes a fall in aldosterone levels to pre-infusion or sub pre-infusion levels 
[28-30].  
This negative effect has also been demonstrated on aldosterone synthase mRNA 
expression in rats over a similar time course 
[31] and appears to be dose related 
[28].   
  Nevertheless, CYP11B2 but not CYP11B1 expression has been shown to 
persist where ACTH has been suppressed indicating that ACTH is not vital for its 
existence 
[32, 33]. Despite the previous evidence, ACTH is still considered an    
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Figure 1.3     Adrenal Steroid Synthesis Pathway 
[34] 
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important physiological trigger of aldosterone production, evidenced by the 
diurnal secretion pattern of aldosterone following that of cortisol. However, no 
feedback loop has been identified as yet 
[35].   
In addition, sodium repletion, potassium loading and increased 
angiotensin II levels have been shown to alter this relationship and increase the 
production of aldosterone in response to ACTH 
[30, 36]. In fact one small study 
showed that blocking angiotensin II production (with captopril) associated with 
ACTH infusion, dampened the aldosterone response 
[35]. 
1.5.2    Angiotensin II and the Renin-Angiotensin System 
In response to low circulating intravascular volume (detected by the 
baroreceptors) and reduced plasma sodium concentration (detected in the 
macula densa) renin is produced and then secreted from the juxta-glomerular 
apparatus.  This forms the starting point of the renin-angiotensin system.  Renin 
then catalyses the conversion of angiotensinogen, produced in the liver, into 
biologically inactive angiotensin I.  Angiotensin I is subsequently converted into 
active angiotensin II by angiotensin converting enzyme (ACE) (Figure 1.4).  ACE 
has gained clinical importance with the development of a class of medication 
called ACE inhibitors (ACEI).  ACEI have been shown to have beneficial effects 
e.g. post myocardial infarction, in heart failure and proteinuric states.  ACE is 
found primarily in the lungs but also in the vascular endothelium and has recently 
been demonstrated in other tissues e.g. myocardium. Angiotensin II is a potent 
vasoconstrictor and also acts within minutes to stimulate the glomerulosa cells to 
secrete aldosterone.     
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Figure 1.4      Basic Schematic Diagram of the Renin Angiotensin 
        System 
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1.5.3    Potassium  
As mentioned previously, potassium influences the interaction of ACTH 
and angiotensin II with glomerulosa cells.  However it also has independent 
effects on aldosterone production.  This has been shown with the use of the 
angiotensin converting enzyme inhibitor captopril.  Captopril was unable to block 
the actions of K
+ allowing the increase of aldosterone synthase mRNA 
expression in rats 
[37]. Figure 1.5 demonstrates the positive correlation between 
potassium levels and aldosterone. 
Studies examining these effects have also examined the levels of ACTH 
and cortisol during K
+ loading; finding that the levels of ACTH and cortisol 
remained unchanged. These data indicate that neither the renin-angiotensin 
sytem nor ACTH are needed for aldosterone production to be induced by K
+ 
loading 
[33]    
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Figure 1.5     The Effect of Potassium on Aldosterone Production  
       in Humans 
[33] 
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“The relation of plasma aldosterone and serum potassium response to an 
infusion of potassium chloride in live normal subjects (correlation 
coefficient 0.62, p<0.01). The potassium chloride was infused at a constant 
rate of 37.5mEq/hr for two hours. The subjects were in balance on a 
10mEq sodium/200mEq potassium diet and were studied supine.” 
[33] 
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In fact, glomerulosa cells are very sensitive to even small increases in 
potassium (K
+) consequently causing large increases aldosterone synthase 
production and aldosterone secretion 
[33, 38, 39].  In order to increase aldosterone 
production, K
+ acts by depolarising the cell membrane causing voltage gated 
Ca
2+ channels to open
 [40].  Successful use of the calcium channel blocker, 
nifedipine to block K
+ effects on Ca
2+ influx and CYP11B2 mRNA production 
confirms this mechanism of action 
[41, 42].  It is then thought that this Ca
2+ influx 
activates calmodulin dependent kinases and in particular Calmodulin protein 
kinase I.  CMKI is concentrated in the zona glomerulosa cells of the adrenal and 
using antagonists (e.g.KN93 and calmidazolium) the effects mediated by K
+ on 
CYP11B2 expressioncan be ameliorated  
[43, 44]. 
 
1.6    Mechanisms of Action 
1.6.1  The MR Receptor  
Classically aldosterone is described as a hormone that acts on the distal 
nephron to increase sodium reabsorbtion.  It does so by diffusing into the cell and 
binding to an intracellular mineralocorticoid receptor (MR).  
The MR belongs to a group of proteins called the nuclear receptor 
subfamily; other members of which include sex-hormone and cortisol binding 
receptors. It is the MR that is considered the mediator of aldosterone’s genomic 
effects. However MR binding is not specific to aldosterone; in fact it has an equal 
affinity for cortisol.  Circulating levels of cortisol are at least 100 times that of    
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aldosterone and therefore in theory it should occupy more MR than aldosterone.  
Since this is not the case, it is reasonable to assume that other mechanisms exist 
to regulate cortisol occupation of the MR 
[45]. In epithelial tissues the expression 
of a type 2 isoform of 11-hydroxysteroid dehydrogenase enzyme (11β-HSD2) 
deactivates cortisol to form 11-cortisone.  11-cortisone cannot bind to the MR 
and so in these cells the MR is thought to preferentially bind aldosterone 
[26, 46]. 
The best characterised action of aldosterone is increased sodium reabsorbtion in 
the kidney.  An electrochemical gradient allows diffusion of sodium into the distal 
nephron epithelial cells via amiloride-sensitive epithelial sodium channels (ENaC) 
present on the apical cell membrane of the kidneys. The Na
+/K
+ -ATPase located 
on the baso-lateral cell membrane then actively transports Na
+ into the 
bloodstream. This increases Na
+ reabsorbtion whilst simultaneously causing 
excretion of potassium into the urine.  Water accompanies the movement of 
sodium and therefore an increase in plasma volume also results 
[25].  
Only a small proportion of ENaC channel synthesised by the cell are 
expressed on the cell surface 
[47].  Therefore this provides potential for a quicker 
response to aldosterone than by an increase in ENaC protein production. 
In the presence of aldosterone, MR dependent effects appear to occur in 
two stages; an early (i.e. before 3 hours) and a late stage (i.e. after 3 hours).  In 
the early stage of aldosterone administration there is an increase in the mean 
opening time and number of ENaC channels at the apical cell membrane 
[48], 
thereby increasing sodium reabsortion in these tissues. However 3-6 hours after    
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exposure increased biosynthesis of ENaC and Na
+/K
+  ATPase results 
[49, 50]. 
This is believed to be responsible for the sustained Na
+ response. 
The MR receptor consists of an N-terminal domain, DNA-binding domain 
and a C-terminal ligand binding domain.  It is the latter of these to which 
aldosterone binds causing a conformational change, followed by dimerisation.  
The complex then translocates to the nucleus 
[25].  Here the DNA-binding domain 
of the MR receptor binds to the hormone-response elements (HRE) and causes 
up-regulation of aldosterone induced proteins (AIPs). Of the AIPs produced the 
serine-threonine kinase SGK1 is most described. SGK1 is phosphorylated and 
activated within 30 minutes of aldosterone administration 
[51]. It is now thought 
that SGK1 increases ENaC surface expression via phosphorylation of the 
ubiquitin protein ligase; Neuronal developmentally down-regulated protein 4 
(Nedd4-2) 
[52]. (Figure 1.6) 
Nedd4-2 is an inhibitory protein that binds to the β and γ subunits of ENaC 
causing its internalisation and breakdown
 [53]. Therefore it’s inhibition by SGK1 
increases expression of ENaC at the cell surface and hence increases Na+ 
reabsorbtion. 
Other AIPs include Kirsten-RasA (Ki-RasA), Corticosteroid Hormone-
induced factor (CHIF), Glucocorticoid-induced leucine zipper (GILZ) and PI3K.  
Ki-RasA is a GTP- binding protein that regulates G-proteins and is a known 
activator of the MAPK1/2 cascade (involved in cell proliferation).  Evidence in 
both renal A6 epithelial cells and rat cardiac myofibroblasts demonstrate an 
increase in active GTP-bound Ki-RasA 
[54, 55] following aldosterone infusion.      
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Figure 1.6  The Classical Mechanism of Aldosterone’s 
Action in Epithelial Cells. 
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However the exact functions of Ki-RasA during aldosterone administration 
are not yet clear. 
CHIF is a member of the one-transmembrane segment protein family 
named FXYD.  It is found mainly in the renal collecting duct and distal colon and 
increases the sensitivity and work rate of the Na/KATPase pump to sodium 
[56].  
As explained above MR receptors are classically described in the distal 
nephron however increasing evidence reports findings in other epithelial (colon, 
salivary glands and sweat glands) and non-epithelial cells (mesangial cells, 
fibroblasts, vascular smooth muscle cells, cardiomyocytes, brain, liver and 
leukocytes) 
[26, 46]. 
This classical view of aldosterone’s mechanism of action is either termed 
“Genomic” or “MR-dependent”. However there is now evidence that 
aldosterone’s effects spread beyond the distal nephron and the MR receptor.  
These non-genomic effects are discussed below. 
1.6.2     Non-Genomic Effects of Aldosterone 
Classical MR activation requires time to take effect because it involves 
gene transcription and protein production.  However, aldosterone’s actions are 
not all thought to occur from this classical genomic pathway.  Effects of 
Aldosterone have been noted within minutes of injection and are therefore 
considered too rapid to be from genomic effects alone.   Some but not all of 
these non-genomic effects appear MR mediated. 
The first description of these rapid non-genomic effects was reported by 
Spach and Streeten more than 40years ago.  They found that aldosterone    
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caused effects on sodium exchange in dog erythrocytes at physiological 
concentrations of aldosterone 
[57]. Since erythrocytes have no nucleus these 
effects could not have been genomic.  Another convincing discovery was made 
from experiments conducted on cutaneous fibroblasts of MR knockout mice. In 
these mice aldosterone caused a rapid increase in the levels of intracellular 
calcium and cAMP [58]. Despite the early discoveries by Spach and Streeten 
further research in this area only really started in the late 1980s.  It was then that 
Human Mononuclear Leukocytes (HMLs) were used to investigate ion transfer in 
response to aldosterone.  Wehling described a significant increase in intracellular  
K
+, Na
+, Ca
2+ and volume within one hour of treatment with aldosterone at 
0.1nmol/l concentration.  This effect was not inhibited by canrenone (an MR 
antagonist) 
[59].  A hypothesis exists that these effects are brought about through 
interaction with a membrane bound receptor however this is yet to be identified 
and sequenced 
[60]. 
  Other evidence suggests that the MR might have a role in these rapid 
non-genomic effects.  Indeed, Eplenerone (a new MR antagonist) has been 
found to block the rapid vasoconstricting effects of aldosterone on mesenteric 
vessels in animal models 
[61]. So perhaps a combination of the two pathways, 
with cross talk between them, might actually be the true situation. 
1.7   Cardio-Renal Effects of RAS 
Animal studies (mainly in rats) have shown deleterious cardio renal effects 
of increased aldosterone levels.  These cardio renal effects include inflammation, 
endothelial dysfunction, increased blood pressure, oxidative stress, fibrosis and    
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increased proteinuria.  However these effects have been demonstrated to be salt 
dependent in animals 
[46, 62-65] but not conclusively in humans.  
Some of these deleterious effects seem to be due to activation of the 
mineralocorticoid receptor (MR) or production of angiotensin II whilst others are 
due to direct effect of aldosterone.  
1.7.1   Myocardial Fibrosis 
MR activation in the heart has been shown to regulate collagen formation, 
activate smooth muscle cells and alter the effects of the adrenergic system 
[26]. 
There is still controversy over the presence of the 11β-hydroxydehydrogenase 
enzyme in addition to the MR, in human hearts but it is known to be present in 
vascular tissue. Without this enzyme we could conclude that cortisol was driving 
the MR effects rather than aldosterone.  But the evidence for aldosterone acting 
via MR’s as cause for cardiac fibrosis in vivo is well recognized
 [66].  
Recent studies examining left ventricular hypertrophy have found an 
abnormal accumulation of fibrillar collagen in the interstitium, perivascular tissue, 
as well as increasing myocardial cell growth.  The presence of this fibrosis is now 
thought to be a consequence of hormone activation rather than haemodynamic 
effects.  This has been demonstrated in vivo where infra-renal aortic banding was 
used to precipitate hypertension and left ventricular hypertrophy but myocardial 
fibrosis was not found histologically 
[67].  In other studies, rats have been given 
intracerebral mineralocorticoid receptor blockers to prevent hypertension whilst 
concurrently being given a peripheral aldosterone infusion.  In these rats cardiac 
hypertrophy and fibrosis did develop 
[68].    
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These effects of aldosterone are, in most cases, salt sensitive, with 
fibrosis only occurring in the presence of increased salt intake 
[46, 62, 63, 69]. 
Unfortunately the mechanisms for this interaction are not yet fully understood. 
One hypothesis is that the high salt levels activate the renin-angiotensin system 
in the myocardium. To support this; increased mRNA levels for angiotensin 
converting enzyme have been reported in vivo and in patients with dilated 
cardiomyopathy
 [70]. 
Other researchers have attempted to determine the mechanism of 
aldosterone induced cardiac fibrosis.  Some in vivo studies using spironalactone 
(an MR antagonist) demonstrated that it could be used to inhibit aldosterone 
induced fibrosis 
[66]. However in rat cardiac fibroblasts spironalactone failed to 
inhibit fibrosis suggesting that at least some of aldosterone's effects were due to 
non-MR effects
[71].  
The time course of these effects in the heart has also been estimated.  By 
8 weeks of aldosterone and salt infusion, marked fibrosis has developed in 
uninephrectomised rat models 
[67, 68]. But prior to this vascular inflammation and 
oxidative stress have been demonstrated and are thought to precede the fibrosis 
[65, 72, 73]. 
1.8   Epidemiology of Primary Hyperaldosteronism 
Functional primary hyperaldosteronism might account for approximately 5-
10% of hypertension in general population and 20% of those with resistant 
hypertension 
[63, 74]. This is a higher incidence than previously thought and follows 
the introduction of the aldosterone:renin ratio (ARR) as a more sensitive    
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screening measure.  In addition, wider screening to include those patients who 
are normokalaemic “essential” hypertensive patients has revealed previously 
unidentified hyperaldosteronism 
[74]. 
 
1.9   Aldosterone to Renin Ratio 
Recently it has been recognised that the proportion of hypertensive 
patients with excess aldosterone is larger than originally thought.  This increased 
estimation might be due in part to the initiation of aldosterone:renin ratio as a 
screening and diagnostic test for hypertension.  In theory the ratio between these 
hormones is a more accurate assessment of the status of aldosterone and the 
renin-angiotensin system than aldosterone alone.  This is because the ratio takes 
into account the sodium and postural effects on levels in the blood.  However the 
ratio is affected by medication in particular angiotensin converting enzyme 
inhibitors (ACEI) and beta-blockers (BB). ACEI increase renin levels via feedback 
mechanisms therefore reducing the ratio whereas BB reduce renin and therefore 
increase the ratio.  
 
1.10  Mortality  
The Consensus study, investigating patients with heart failure, found that 
baseline aldosterone concentrations above the median had a significantly higher 
mortality compared to those below (55% vs. 32%, p<0.001) 
[75] .  It also 
demonstrated a reduction in mortality, due to worsening heart failure, in patients    
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treated with enalapril. This was the first large randomized controlled trial to 
demonstrate a potential link in humans between aldosterone and mortality. 
  Subsequently, human studies have demonstrated a benefit from 
aldosterone antagonists. The RALES study demonstrated a 30% reduction in 
mortality of severe chronic heart failure patients with the use of spironalactone 
[76].  Another large human study was the EPHESUS study, this enrolled patients 
with heart failure post myocardial infarction. They demonstrated a reduction in all 
cause mortality but this time with eplenerone (a new selective Aldosterone 
blocker) 
[77].    
 
1.11  Magnetic Resonance Imaging (MRI) 
1.11.1  Physics 
Conventional MRI uses excitation of hydrogen atoms to form images.  
Hydrogen is used predominantly due to its abundance within our bodies (80% 
water) and due to the fact that it has the largest magnetic moment.  However any 
atom with an odd number of protons can be utilised 
[78]. With only 1 proton in a 
hydrogen nucleus, it is unbalanced and a net charge and spin is produced. This 
in turn produces a magnetic charge the strength and direction of which is called 
magnetic moment 
[79]. These charged nuclei repel or attract each other 
depending on their orientation.  At rest the hydrogen atoms and protons are 
aligned in different directions however when the human body is put into a strong    
  44 
magnetic field the protons line up. They can line up parallel or anti-parallel to the 
main magnetic field depending on their energy state (Figure 1.7). 
The protons also precess or “wobble” under the influence of an external 
magnetic field. This precession causes the nucleus to orbit around the direction 
of the external field (B0) The frequency of the precession can be calculated from 
the equation below called the Larmor frequency 
[78]. 
ω0 = γ Β0  
Where: ω0 = Precessional or Larmor frequency. (MHz)  
 γ = Gyro Magnetic Ratio. (MHz/T) or magnetic moment 
Β0 = Magnetic field strength. (T)   
The majority of protons align parallel with the magnetic field and this is called 
net magnetisation vector (NMV).  As the magnetic strength increases so does  
the percentage of protons parallel to Β0, therefore increasing the NMV 
[79]. 
1.11.2  Excitation 
For a 1.5 Tesla machine the Larmor frequency is 63 MHz for Hydrogen 
ions.  A radio frequency (RF) pulse at that frequency is provided to excite the 
protons.  This causes the targeted particles to resonate and increases the 
number of high energy particles.  The increase in energy state allows more 
protons to oppose B0 therefore changing the net vector.  
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Figure 1.7  Magnetic Field Effects on individual protons 
within the MRI scanner 
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Figure 1.8  Schematic diagram to demonstrate the 
directionof main MR axis (B0), and x and y axis 
with respect to the patient in the MR scanner. 
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1.11.3   T1 Relaxation  
This process occurs after the RF pulse has been given and the protons 
excited to 90
◦ i.e. moved into the x-y plane.  The protons then lose the energy 
received by the RF pulse over time and return to their original position (i.e. 
parallel to B0/the z plane) (Figure 1.9).  The energy released takes the form of 
radio waves and a small amount of heat. The time for 63% of the nuclei to return 
to their longitudinal magnetisation is called the T1 recovery time.  This time is 
constant for a particular tissue e.g. fat or water
[79]. 
1.11.4   T2 Decay  
T2 Decay is caused by the interaction of the magnetic fields around each 
atom.  To understand T2 decay, it is important to understand phase coherence.  
Once the RF pulse has been given the particles not only gain enough energy to 
move into the x-y plane, the magnetic moments also move into phase.  That is to 
say that if you looked at the nuclei from above, the protons would be spinning in 
a circle, all at the same point on the circle (Figure 1.10 A).   
After the RF pulse is given you would see that the protons were all at the 
same place on the circle at a given time.  Over time the nuclei will interact so that 
in the end the protons would be seen in all different places on the circle.  
Therefore the net magnetisation vector in x-y plane would cancel out. (Figure 
1.10E) 
The T2 decay time is the time it takes for 63% of the transverse 
magnetisation to be lost, due to de-phasing.    
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Figure 1.9   T1 relaxation 
[78] 
 
 
 
 
Figure 1.10  T2 Decay 
[78] 
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The T2 decay time is intrinsic and constant for a particular tissue.  
The processes of T1 relaxation and T2 decay occur in different planes but 
at the same time.  Once both processes of relaxation have occurred the NMV is 
back at B0 and the protons are spinning out-of-phase.  
1.11.5  Image Acquisition 
Faraday’s law states that “a change in magnetic flux through a closed 
circuit induces an electromotive force” and consequently a current 
[79]. It is this 
current that is picked up by a receiver coil and interpreted into the MRI image.  A 
receiver coil is placed on the patient over the part of the body that is being 
imaged prior to them entering the scanner.  This receiver coil must be at 90
◦ to B0 
in order to generate the current in the coil and one that is not overpowered by the 
signal from the main magnetic field.   
Cardiac function is evaluated using cine gradient echo sequences. 
Steady-state free precession (SSFP) gradient echo sequences have largely 
replaced spoiled gradient echo sequences for this purpose. Different trade 
names for these SSFP sequences are used by different manufacturers. Siemens 
have called theirs TrueFISP (True Fast Imaging with Steady-state Precession). 
1.11.6  Gadolinium 
Gadolinium is a chemical that is used in cardiac MRI scanning to identify 
areas of ishaemia and fibrosis.  It reduces the T1 time of the tissues that absorb 
it.  Therefore early Gadolinium scans can identify areas that are slow to take up    
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Gadolinium (so called microvascular obstruction or MVO) and late Gadolinium 
enhancement identifies areas of fibrosis. 
1.11.7  Advantages of MRI Compared with Echocardiography 
Echocardiography has been used for many years with the accompanying 
confidence and ease of use that experience brings.  However echocardiography 
is affected by intravascular fluid status and adiposity, and can over-estimate left 
ventricular mass; whereas MR is volume independent and clear images are 
available in a greater proportion of patients (including those with a large body 
surface mass index). 
 
1.12  Spectroscopy 
  Conventional MRI is based on the magnetic fields generated by the 
Hydrogen atoms within body.  However, as indicated above, any nuclei with an 
odd number of protons can be studied (Figure 1.11).  Spectroscopy is used to 
non-invasively quantify phosphate containing molecules found within regions of 
the heart in vivo 
[80].   
In our study 
31
P Spectroscopy was used to study high energy phosphate 
groups within the cardiac ventricular wall (e.g. phosphocreatinine (PCr) and 
adenosine tri-phosphate (ATP)) that are responsible for providing immediate 
energy for cardiac myocytes.  The metabolic reaction used to generate these 
high energy phosphate groups is called the creatine kinase reaction (Figure 
1.12).     
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Isotope  Symbol 
Spin 
Quantum 
number 
Gyro Magnetic 
Ratio (MHz/T) 
Hydrogen  
1
H   1/2   42.6  
Carbon  
13
C   1/2   10.7  
Oxygen  
17
O   5/2   5.8  
Fluorine  
19
F   1/2   40.0  
Sodium  
23
Na   3/2   11.3  
Magnesium  
25
Mg   5/2   2.6  
Phosphorus  
31
P   1/2   17.2  
Sulphur  
33
S   3/2   3.3  
Iron  
57
Fe   1/2   1.4  
 
 
Figure 1.11  MRI “Friendly” Elements 
[78] 
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Figure 1.12  The Creatinine Kinase Reaction 
[81] 
 
Key:   ATP = Adenosine triphosphate 
ADP = Adenosine diphosphate 
Pi = inorganic phosphate 
PCr  = Phosphocreatinine 
Ox-phos = oxidative phosphorylation 
MiCK = mitochondrial kinases 
MMCK = myofibrillar kinases 
ATPase = ATP hydrolysis    
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The chemical bonds and structure of the tissues under examination affects 
the magnetic shielding of the nucleus and consequently its magnetic frequency.  
Therefore different chemicals resonate at slightly different frequencies despite all 
containing the 
31
P ion. This array of magnetic frequencies provides us with a 
spectrum of results allowing differentiation of ATP, PCr etc. Unfortunately 
31
P has 
a lower intrinsic MR sensitivity than 
1H and the low concentrations of substances 
examined in 
31
P spectroscopy limits the depth to which 
31
P signals can be 
accurately interpreted.  In the heart this restricts us to spectrum received from the 
anterior ventricular wall or septum 
[80]. 
Phosphocreatinine is stored in muscle cells and provides a store of 
immediate energy for the myocytes. The cycle above is controlled by the enzyme 
creatinine kinase that phosphorylates ADP and dephosphorylates ATP to provide 
the energy.   
Unfortunately when acquiring the spectra our voxels often included blood 
as well as the ventricular wall.  Blood contains high levels of ATP so it was 
important to subtract the contribution of blood ATP from the total ATP results.  
We were able to do this by applying the equation below: 
 
β-ATP correction for blood      =      β-ATPheart – ( 0.15 x 2,3 DPGblood ) 
[82] 
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1.12.1  Method 
Using the MRI scanner, a 
31
P transmitter coil is used to provide a uniform 
excitation field.  A 
31
P surface coil is positioned over the heart on the anterior 
chest wall.  Once the patient is returned to the scanner, 2 localiser MR images 
are performed (multi log and vertical long axis views).  A voxel grid is then placed 
over the heart in maximal systole with the maximum amount of myocardium in 
each voxel.  A Shim field is also applied over the ventricle to ensure optimal 
magnetic field uniformity 
[80]. 
In a human heart, 
31
P spectrum, (Figure 1.13) a large PCr peak is typically 
seen at 0ppm followed by three peaks corresponding to γ-ATP (-2.7ppm), α-ATP 
(-7.8ppm) and β-ATP (-16.3ppm).  Peaks for 2, 3 diphosphogycerate (DPG) and 
inorganic phosphate (Pi) can also be obtained 
[80].  2,3 DPG is particularly useful 
in order to determine the proportion of the ATP peak contributed to by the 
ventricular blood within the voxel (see previous equation).   
Quantification of each peak is performed by applying best fit curves and then 
measuring the area under the curve.  
The PCr/ATP ratio is considered the best measure of energy metabolism 
in the cardiac myocytes.  A number of studies have now been performed 
investigating cardiac spectroscopy and the majority of these have determined a 
normal value for PCr/ATP ratio of 1.83 +/- 0.12 
[80]. 
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Figure 1.13    An Example of a Cardiac 
31
P Spectrum 
 
MR Spectrum “is a plot of the MR signal intensity as a function of MR frequency, 
typically measured in parts per million (ppm) relative to a resonant frequency of a 
reference compound.”  
[83]   
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1.13    MR Spectroscopy in Clinical Practice 
1.13.1  Left Ventricular Hypertrophy and Heart Failure 
Chronic heart failure is consistently associated with a reduced PCr/ATP 
ratio in animals and humans regardless of the underlying pathology 
[84-86].  This 
relationship has been shown in some studies to be proportional to the degree of 
heart failure 
[87].  Other cardiac pathologies with lower than normal PCr/ATP 
ratios include ischaemic and idiopathic dilated cardiomyopathy 
[82] and possibly 
left ventricular hypertrophy 
[88].  We know that for many patients who develop left 
ventricular hypertrophy, unless treated, it progresses causing reduced 
contractility and symptoms of heart failure.  It has been hypothesised that an 
alteration in high energy phosphate metabolism is involved in this loss of function 
and contractility. A study in 2006 was performed to compare control patients 
(with normal left ventricular mass index (LVMI)), patients with LVH and LVH plus 
chronic heart failure (CHF).  A reduction in PCr/ATP ratio by 30% was 
demonstrated in both the LVH, and LVH and CHF groups compared to controls.  
However, no significant difference was noted between the two LVH groups 
[88].  
Others have also demonstrated a difference between LVH and LVH and CHF in 
the context of high energy phosphate metabolism but have used the definition of 
CK forward flux as a marker of this instead of PCr/ATP ratios 
[88, 89].  These 
findings confirm the initial findings in animal studies
 [84, 85].  One of the reasons for 
this change in metabolism could be the reduction in the enzyme creatine kinase 
in LVH
 [85, 88].    
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Left ventricular hypertrophy (LVH) can be pathological or physiological.  In 
athletes left ventricular hypertrophy is a physiological adaptation where 
contractility is preserved despite the increase in size.  Investigation into high 
energy phosphate metabolism in this group revealed no difference between 
athletes and controls without LVH in terms of their high energy phosphate 
metabolism 
[90].  These findings, along with the fact that the systolic and diastolic 
function of the athletes was within the normal range, suggests that it is the 
functional capacity of the ventricle rather than the size per se, that causes a 
change in energy metabolism. 
1.13.2  Uraemic Cardiomyopathy 
Uraemia is associated with left ventricular hypertrophy, as part of a triad 
called “Uraemic Cardiomyopathy”.  Hypertension, arterial calcification and fluid 
overload are associated with LVH but LVH has repeatedly been shown to be an 
independent risk factor for both cardiovascular morbidity and mortality 
[11, 91, 92]. 
Limited information is available about the effect of uraemia on high energy 
phosphate metabolism but in one study, uraemia was also associated with a 
reduction in PCr/ATP ratio. However the same study also demonstrated that this 
was not an irreversible process.  In fact following a kidney transplant the 
PCr/ATP ratio returned to that of normal patients 
[87]. 
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1.14  Transforming Growth Factor Beta 
Transforming growth factor beta (TGF-β) forms part of the transforming 
growth factor superfamily of cytokines.  Other members of this family include 
activins, inhibins and bone morphogenetic proteins (BMP). Cytokines are defined 
as signalling molecules that are used in cellular communication and are vital for 
cell growth, repair and death.  TGF-β in particular is involved with cell cycling, 
tissue repair and when over-expressed it can induce fibrosis.   It is for these 
reasons that it has become a focus of scientific research over the past 30 years 
and raises the hope of a possible therapeutic target to prevent fibrosis and aid 
wound healing. 
TGF-β was first identified over 25 years ago when it was isolated from 
platelets by Assoian et Al
 [93]. It is now known that the first discovered isoform 
was TGF-β1. However, TGF-β exists in 3 isoforms in mammals; TGF-β1, TGF-β2 
and TGF-β3;all with similar biological actions. The isoforms are 60-80% 
homologous and are encoded by different genes 
[94].  All 3 isoforms are 
synthesised predominantly as homodimers although heterodimers of  TGF-β1 
and TGF-β2 has been identified in pigs 
[95]. 
TGF-β2 was identified a few years after TGF-β1, when it was isolated from 
porcine platelets 
[95], human glioblastoma cells 
[96] and bovine bone 
[97].  TGF-β3 
was characterised a year later in 1988 
[98]. Two other isoforms (TGF-β4 and TGF-
β5) have now been identified but have not yet been found in mammals 
[99].  On 
this basis they have been disregarded from further discussion in this chapter.    
  59 
1.14.1  Biosynthesis 
All three TGF-β isoforms are synthesised initially as a large protein pre-
cursor molecule (390 amino acids in length).  This consists of a secretory pro-
protein (20-30 amino acids), latent associated peptide (LAP) and an active C-
Terminus (112-114 amino acids) 
[100]. Figure 1.14 provides a schematic diagram 
of the pre-cursor molecule. 
After production, the TGF pre-cursor molecule is processed in the golgi 
apparatus and the pro-protein removed.  Now a biologically inactive form can be 
formed by the bonding of a TGF-β homodimer to a latency-associated peptide 
(LAP) homodimer 
[101] (Figure 1.15). The inactive form can either be secreted 
alone or with latent TGF-β binding protein. Latent TGF-β1 cannot bind to TGF- β 
receptors; it requires activation via removal of the LAP homodimer.  The 
mechanisms for this activation in vivo are not clear but in vitro temporary 
acidification or alkalinisation, extremes of temperature, or presence of certain cell 
types (e.g. activated osteoclasts, monocytes/macrophages) are required 
[102].  It 
has also been shown that TGF-β can reestablish latency by recombining with its 
LAP however the conditions and exact mechanisms for this are also ill-defined 
[103]. 
The active form is a homodimer of the TGF- β1 C-terminals linked by 8 of 
the 9 cysteine residues forming disulphide bonds to produce the characteristic 
cysteine-knot structure of the TGF superfamily. While the 9
th cysteine residues 
bond to ensure dimeric linkage between the two C-terminals in TGF- β1 
[100]
. 
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Figure 1.14  A Schematic Diagram of a TGF-β Pre-cursor  
      Molecule 
 
The thinner black line represents the secretory pro-protein molecule that is 
cleaved in the golgi apparatus.  The thicker grey line represents the latent 
associated protein (LAP) and the rectangles represent the C-terminals that later 
form the active component of TGF-β.  The letters “C” within the rectangle 
represent the nine Cysteine residues present within the C-terminal. 
cc  cc  cc  cc  c    
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Figure 1.15   A Schematic Representation of Latent TGF-β.   
 
This can either be secreted alone or in combination with latent TGF- β binding 
protein (LAP). 
 
Homodimer 
of LAP 
Homodimer of C-terminals, 
Joined by disulphide 
bonds 1.14.2  Expression of TGF-β1 
Most tissues within the body secrete and/or express one or more of the 
TGF-β isoforms.  TGF-β1 was first identified in platelets and it is here that the 
highest concentrations have been identified (especially in human placenta; 
20mg/kg) 
[94].  In cardiac tissue; fibroblasts, myocytes, macrophages, 
lymphocytes and platelets have all been shown to release TGF-β1 
[104].   
1.14.3  TGF-β Receptors 
TGF-β1 and TGF-β2 have been found to bind to 3 cell surface receptors; 
Type I, II and III.  Type I and II are transmembrane serine threonine kinases 
classified by weight (55 kDa and 70 kDa respectively). The Type III receptor is a 
much larger membrane anchored proteoglycan called betaglycan.  Type III 
receptors have been shown to regulate the accessibility of TGF-β to the Type I 
and II receptors especially to TGF-β2 
[105, 106]. However Type III receptors are not 
essential for TGF-β regulation. This has been demonstrated using rat skeletal 
muscle myoblasts;  TGF-β mediated increased extracellular matrix production in 
these cells despite the absence of Type III TGF-β receptors 
[107]. 
Type I and II TGF-β1 receptors are both required for TGF-β1 binding; 
occurring as heterotetrameric compounds that spans the cell membrane 
[108].  
This is because once TGF-β1 binds to the higher affinity Type 2 receptor; it 
activates the lower affinity type 1 receptor via phosphorylation.  All the 
intracellular pathways that follow receptor activation have not been fully 
elucidated, but Smads have been implicated as the dominant pathway. SMADs    
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are intracellular proteins that act as transcription factors when activated by a 
member of the TGF-β superfamily.  However there are many different SMADs 
and these have different roles in the transmission of signals from the TGF β 
superfamily receptor to the nucleus. Smad 2 and 3 form complexes with activated 
TGF-β receptor complex; are phosphorylated and then released.  Once released, 
they complex with Smad4 and are transported to the nucleus via nucleoporins.  
Here they act to stimulate gene transcription either directly or in collaboration with 
other transcription factors 
[104, 106] (Figure 1.16).  Smad 6 and 7 have been 
identified as inhibitors of this cascade and potentially form part of a negative 
feedback loop 
[109-111].  They compete with Smad 3/4 for the binding site of the 
TGF-β receptor 1 and increase its degradation 
[111]. TGF-β has also been found 
to increase Smad 7 transcription leading to the hypothesis that this forms part of 
a negative feedback loop 
[112]. 
Other intracellular pathways activated by TGF-β ligand receptor binding 
have been indentified but evidence for their exact roles in TGF-β’s biological 
effects are inconclusive.  Some of the non-Smad pathways investigated include; 
ERK1/2 (extracellular signal regulated kinase 1/2, JNK (c-Jun N-terminal kinase) 
and p38; all of which inhabit the mitogen-activated protein kinase family 
[106]. 
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Figure 1.16   A Schematic Diagram of TGF-β1 Binding and 
the Intracellular Smad Pathways that follow. 
 
Key:   The grey arrows represent phosphorylation  
The black arrows represent binding.    
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1.14.4    TGF-β and Fibrosis 
TGF-β has been shown to up-regulate many elements of the extracellular 
matrix that are essential for wound healing.  Some of these include collagen 
(types I and III), fibronectin 
[113], osteopontin, chondroitin and tenascin 
[114]. In fact 
TGF-β1 is probably one of the most potent stimuli for collagen production being 
shown to be more potent than platelet derived growth factor, insulin derived 
growth factor and basic fibroblast growth factor 
[115].  Under normal 
circumstances TGF- β1 production is terminated once tissue healing is complete.  
However, during fibrosis it is thought that this negative feedback mechanism is 
altered or damaged allowing over expression of TGF- β1.  The negative feedback 
pathway has not been fully elucidated as yet but Plasminogen activator -1 (PA-1) 
(an important inhibitor of extracellular matrix formation) is up-regulated by TGF-β1 
[116].  Also TGF-β1 has been shown to self regulate its own mRNA expression and 
protein synthesis demonstrating another possible negative feedback mechanism 
[108]. 
A TGF-β1 knockout mouse has been developed but unfortunately the 
animals developed generalised inflammation and wasting, and died at about 3 
weeks of age 
[117].  Therefore they were unsuitable for the study of adult rat 
pathology.  Later on an alternative animal model, with over expression of TGF-β1 
in cardiac tissue, was developed (by gene transfer).  In these mice, over 
expression of TGF-β1 was found to cause cardiac hypertrophy and fibrosis 
[118]. 
Other similar animal models have demonstrated a link between over-expression 
of TGF-β1 and fibrosis in other organs e.g. kidneys and lung 
[119, 120].  Evidence to    
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implicate over-expression of TGF- β1 as a cause of fibrosis extend beyond the 
findings described above. Researchers found that an increase in TGF-β1 levels 
proceeded extracellular matrix production and fibrosis, and that high levels of 
TGF-β1 were found in areas of fibrosis 
[121, 122].  Mice injected with recombinant 
TGF-β1 developed scarring and fibrosis of their hearts, lungs, kidneys, bones, 
pancreas, thymus and at the injection site 
[123]. This provides more evidence that 
TGF- β1 is a stimulus for multi-organ fibrosis.  
1.14.5    The Renin Angiotensin System (RAS) and TGF-β 
Angiotensin II is the most studied RAS hormone in the context of TGF-β 
production and release in the heart.  Recent research has discovered that 
Angiotensin II is a potent stimulator of TGF- β1 release from rat cardiac 
fibroblasts
 [124]. However little is known about the regulation of TGF-β1 release 
although prolonged angiotensin II infusion and local angiotensin II production 
post-infarction have been shown to up-regulate TGF-β1 levels in rats 
[125, 126]. 
Recently research has been conducted examining the effect of 
aldosterone with respect to TGF- β1 in humans with chronic kidney disease. This 
demonstrated a reduction in urinary TGF- β1 and proteinuria following 
spironalactone administration. They concluded that spironalactone may have a 
role in preventing TGF- β1 mediated renal fibrosis 
[127]. Further research is 
required to prove a link between aldosterone, TGF- β1 and cardiac fibrosis in 
humans however. 
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1.15   Aims and Hypothesis 
The aims of this project were: 
·  To examine the relationship between aldosterone and left ventricular 
hypertrophy in humans 
·  To determine the long term prognosis of patients with renal dysfunction 
and a raised renin/aldosterone level 
·  To examine the association between aldosterone, sodium, TGF-β1 and 
cardiac fibrosis in rat ventricle tissue slices. 
 
The hypotheses include: 
·  High aldosterone levels predispose to left ventricular hypertrophy in the 
presence of uraemia 
·  In the presence of renal dysfunction, a raised renin/aldosterone level 
reduces survival rates  
·  In the presence of a high sodium level, aldosterone associates with 
increased TGF-β1 gene expression, causing increased TGF-β1 levels and 
subsequently cardiac fibrosis 
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Chapter 2:  Generic Methods 
2.1   Introduction 
Three studies are included within this project:  
1) West of Scotland Kidney Disease Study – A follow-up survival analysis of 
patients enrolled in a study in the late 1990s, to investigate cardiac disease in 
patients with chronic renal failure. Any relationship between the renin-
angiotensin system and survival/LVH were then examined. 
2) Aldosterone Study – A side-line project using data from patients enrolled in 
a PhD cross-sectional prospective study. This project examined the 
relationship between aldosterone and left ventricular hypertrophy in the 
presence of uraemia. 
3) Rat Heart Slice Study – This study included work up of a new technique 
(within the department) to incubate slices of rat ventricle for subsequent 
analysis.  Following this, the slices were used to examine the relationship 
between aldosterone, salt and cardiac fibrosis/TGF-β1 expression. 
 
2.2   Clinical Studies 
All patients were recruited from the Western Infirmary Hospital in Glasgow.  
Ethical and Research and Development approval for the Aldosterone Study was 
gained by Dr Rajan Patel as part of his PhD project.    
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Ethics approval for the West of Scotland Kidney Disease (WKD) study was 
gained at the time of study in the 1990s from the Hospital Ethics Committee 
[128]. 
 
Exclusion criteria for both clinical studies included: 
·  Those under the age of 18 years old 
·  Prisoners  
·  Those unable to give informed consent (e.g. learning difficulties, 
severe dementia) 
·  Pregnancy 
 
Specific exclusion criteria for Magnetic Resonance Imaging included: 
·  Presence of metallic, mechanical or magnetic implants 
·  Patients unable to lie flat for the duration of the scan 
·  Claustrophobia preventing insertion in to the scanner 
·  Abdominal girth larger than the internal diameter of the scanner 
 
Routine investigations preformed at initial research booking visit included: 
·  Venepuncture – This was performed for routine haematology (full blood 
count and HbA1c) and biochemistry (urea and electrolytes, calcium, 
phosphate, albumin, C-reactive protein, glucose, troponin I, parathyroid 
hormone and lipid profile). Any additional blood was aliquoted, centrifuged 
and stored at -80ºc within 20mins of venepuncture.  This was thawed as    
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required, for additional specialised investigations, as per the study 
protocol.  
·  Renal function was calculated from the serum creatinine using the 
Cockcroft-Gault formula in the West of Scotland Kidney Disease study and 
MDRD6 formula in the Aldosterone study.  
·  Blood pressure – An average of three readings were taken after 10 
minutes of rest (seated for the WKD study and supine for the Aldosterone 
study) 
 
2.3   Echocardiography 
Echocardiography was performed by an experienced echocardiographer 
using an Acuson 128 Siemens machine.  Images and data collected were then 
analysed by a single experienced observer.  All dialysis patients were scanned 
24 hours after dialysis to ensure comparability and standardization of fluid status. 
Left ventricular (LV) dimensions and mass were calculated from two-dimensional 
M-mode images using the American Society of Echocardiography 
recommendations 
[129].   
The LV mass calculation used was that validated by Devereux and 
Reichek 
[130]: LV mass = 1.04 x [(IVSTd + PWTd +LVIDd)
3 – LVIDd
3] – 13.6g. 
Where IVSTd is the interventricular septal thickness in diastole, PWTd is the 
posterior wall thickness in diastole and LVIDd is the left ventricular internal 
diameter in diastole.    
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Left ventricular mass index (LVMI) was then determined by indexing the 
LV mass to body surface area (BSA). Dubois formula for body surface area: BSA 
= 0.20247 x height(m)
0.725 x weight(kg)
0.425 [131]
. Based on this calculation we 
could then determine which patients had LV hypertrophy (LVH).  In men LVH was 
defined as a LVMI of greater than 131g/m
2 and in women as greater than 
100g/m
2 [132]. The geometry of the LVH was also calculated and depended on the 
relative wall thickness (RWT) as classified by the American Society of 
Echocardiography criteria: RWT = [(2 x PWTd) / LVIDd ]. Where PWTd is the 
posterior wall thickness in diastole and LVIDd is the left ventricular internal 
diameter in diastole. 
In the presence of LVH, if the RWT was greater than 0.45cm then it was 
classified as concentric hypertrophy, and if it was less than 0.45cm then it was 
eccentric hypertrophy.  
 
2.4   Cardiac Magnetic Resonance (CMR)  
All CMR images were taken using a 1.5 Tesla Siemens Sonata MRI 
scanner for the Aldosterone study.  Patients were asked to fill in a safety 
questionnaire prior to entry into the scan room and to remove any metallic 
objects from their possession. 
CMR was performed on a post dialysis day for those on dialysis to ensure 
standardisation for the same reasons as for echocardiography
[2].    
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2.4.1  Patient Positioning 
Patients were positioned head first and supine on the scanner table.  A 
receiver coil was then placed on their anterior chest and strapped in position (to 
prevent movement during the scan). ECG leads were placed on the patient’s 
chest to allow R wave recognition, enabling ECG-gating throughout. 
Instructions were given for breath holds (during image acquisition) to reduce 
respiratory motion artefact. 
2.4.2   Image Acquisition 
All images were acquired using Siemens technology steady-state free 
procession (TrueFISP) imaging and were ECG-gated.   
Imaging parameters were standardised: 
  Repetition Time     3.14ms 
  Echo time      1.6ms 
  Flip angle      60ºc 
  Voxel size      2.2x1.3x8.0mm 
  Field of view     340mm 
2.4.3  CMR protocol  
1.  Initially a multi-slice, ECG–gated, localiser image was taken in expiration.   
2.  Using the localiser image with the best view of the ventricles, a vertical 
long axis (VLA) image was planned.  This was done by lining up the apex 
of the left ventricle with the mid point of the mitral valve.    
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3.  Next the VLA image was used to plan a horizontal long axis (HLA) view.  
To do this, a line was drawn through the apex and the midpoint of the 
mitral valve. 
4.  From the HLA image, 3 short axis (SA) views were obtained.  The 3 slices 
were planned by drawing a straight line across the atrio-ventricular groove 
separating the atria and ventricles.   
5.  Cine images were then acquired in the HLA, VLA, and left ventricular 
outflow tract orientation using these 3 SA views acquired above. 
6.  As before the HLA (4-chamber) cine image was used to plan the short axis 
slices.  These were planned as previously described.  Once the first SA 
cine image was acquired further slices (each 8mm deep with a 2mm gap) 
were performed in the same axis at 10mm intervals towards the apex until 
the whole ventricle had been covered. (Figure 2.1) 
 
2.5  Image Analysis 
A single, experienced, non-blinded, observer (Dr Rajan Patel) analysed all 
CMR images. 
2.5.1  Mass and Function 
Epicardial and endocardial borders of the left ventricle, in end systole and 
diastole, were traced manually from the short axis images. Calculations were 
then performed using Argus Siemens Software to determine left ventricular mass, 
left ventricular volumes and ejection fraction.  Left ventricular mass and volumes    
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were indexed to the patient’s body surface area.  This was calculated using the 
Dubois formula as in echocardiography. 
 
2.5.2  Definition of Left Ventricular Ejection Fraction (LVEF)  
Left ventricular ejection fraction was calculated using the formula below: 
LVEF =   EDV – ESV      x 100 
            EDV 
 
 
Where EDV is the end diastolic volume and ESV is the end systolic volume. 
2.5.3  Definition of Other Left Ventricular Abnormalities 
Left ventricular hypertrophy (LVH) is defined as a left ventricular mass 
index (LV mass/BSA: LVMI) of > 83.3g/m
2 in males and >66.8 g/m
2 in females. 
LV dilatation is defined as EDV/BSA > 111.7ml/m
2 in males or 99.3ml/m
2 in 
females or an ESV/BSA greater than 92.8ml in males or 70.3ml in females.  
These values have been determined from previously published LV dimension 
data in healthy volunteers and have been used in previous research at our unit 
[133, 134]. 
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Figure 2.1   Calculation of LVMI and Ejection Fraction from 
CMR Images.    
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A CMR horizontal long axis view of the heart, with a schematic representation of 
the position of the short axis cine loop slices.  At the inferior end of the arrow are 
the short axis views, with the epicardial and endocardial borders of the left 
ventricle delineated. 
2.6   Radioimmunoassay for Aldosterone 
Serum aldosterone was measured for the Aldosterone study using a 
(Coat-a-Count, Siemens, Los Angeles) radioimmunoassay.  This procedure was 
closely supervised by a technician trained in the handling and disposal of 
radioactive substances (Mary Ingram, Glasgow University, BHF building). 
Serum stored at -80ºc was thawed and 200 l from each sample were alloquoted 
for assay. 
2.6.1   Method 
·  Reconstitute each vial of 
125I Aldosterone (total counts at iodination 
40,000cpm) with 110ml of distilled water. Let it stand for 10mins then 
gently invert to mix. 
·  Reconstitute the standard solutions; A with 6ml of distilled water and B-G 
with 3ml of distilled water. ( Standar A=0ng/dl aldosterone, B =2.5ng/dl, 
C=5ng/dl, D=10ng/dl, E=20ng/dl, F=60ng/dl and G=120ng/dl) 
·  Label seven antibody coated 12x75mm polypropylene tubes “A-G”  
·  Into each tube, place 200microlitres of the appropriate standard solution     
·  Label another tube “total count”    
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·  Pipette 1ml of 
125I aldosterone into each of the eight tubes and vortex 
briefly 
·  Add 200microlitres of the patients thawed serum to the remaining 
appropriately labeled 12x75 polypropylene antibody coated tubes  
·  Again, add 1ml of 
125I aldosterone to each tube containing patient serum 
and vortex briefly 
·  Store at room temperature for 18 hours  
·  After the 18 hours, remove any excess moisture in the tubes (except from 
the total count tube). This involves decanting the tubes thoroughly and 
then using a foam decanting rack to allow the tubes to drain for 2-3min. 
Then strike the tubes sharply on absorbent paper to shake off all residual 
doplets. 
·  Use an automated gamma counter (1470 WALLAC Wizard, GMI, Ramsay, 
Minnesota, USA) and count for 1minute. Calculate the standard curve, 
total count and aldosterone levels in the serum samples.  Tthe results are 
in nanograms/decilitre (ng/dl) of aldosterone. 
·  Calculate, record and appropriately dispose of all solid and liquid 
radioactive waste to comply with current safety requirements. 
·  The quoted normal aldosterone values are 4-31ng/dl standing and 1-16 
ng/dl recumbent for a normal sodium intake (6-25  g/day).  
·  Samples with an aldosterone concentrations above the standard G 
concentration (i.e.120ng/dl) should be diluted and re-assayed to ensure 
accurate results or they should be reported as >120ng/dl    
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2.6.2  Intra-Assay Reproducibility 
Reproducibility was demonstrated by repetition of the standard curve 
solutions within and between different assays, as well as calculation of the 
standard curve correlation co-efficient (R=1.0 in both of the two assays used). 
Serum samples with known concentrations of Aldosterone were also used. 
Repeat assays of outlier results were performed at 0.5 and 0.25 times the 
original serum concentration as per the manufacturer’s guidelines.  The results 
are shown in Figure 2.2. Unfortunately despite dilution the Outlier 2 results were 
still >120ng/dl and therefore were likely to be subject to increased error (as such 
these results were therefore reported as >100ng/dl for the purpose of analysis). 
 
2.7  ECG 
As part of the Aldosterone Study a standard 12-lead ECG was taken 
during the hospital visit by Dr Rajan Patel. It was recorded at 25mm/s and 
1mV/cm.  During the recording the patient was at 45º and standard lead 
placement was adhered to. Analysis was also carried out by Dr Rajan Patel (un-
blinded). QT dispersal was measured on 3 separate ECG recording and 
calculated using University of Glasgow, ECG interpretation algorithm (Burdick 
Atria 6100, US). 
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2.8   Exercise Tolerance Test  
All the patients in the Aldosterone study underwent an exercise treadmill 
test according to a standard Bruce Protocol.  A 12 lead ECG and blood pressure 
were recorded at rest prior to the test.  The ECG recording was then continued 
throughout the test and the blood pressure was measured at specified intervals 
and at maximal exertion.  The following measurements were used for 
interpretation: total exercise time achieved, maximal heart rate and systolic blood 
pressure, ST changes and symptoms limiting exercise. The test was halted if the 
patients experienced angina, breathlessness, fatigue, dizziness or if there were 
any of the following ECG changes; ST depression ≥3mm, ventricular tachycardia  
or fall in blood pressure ≥30 mmHg or a rise in systolic blood pressure 
≥230mmHg.  The test was considered inconclusive if the patient’s heart rate 
failed to reach 85% of the predicted heart rate before the test was terminated. 
No medications were stopped prior to undergoing this treadmill test.  This test 
was conducted and analysed by Dr Rajan Patel. 
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  Original 
Aldosterone  
result 
(ng/dl) 
2
nd Assay result at 
0.25 concentration 
(ng/dl) 
2
nd Assay result at 
0.5 concentration 
(ng/dl) 
Outlier 1  152.9  65.2 (270.4)  141.2 (282.4) 
Outlier 2  617.4  133.7 (534.8)  286.0 (572.0) 
  
 
 
Figure 2.2   Results table containing outlier readings of 
serum aldosterone concentration, obtained 
using the aldosterone radioimmunoassay (ng/dl)  
 
The result in brackets is the calculated original serum concentration of 
aldosterone in the sample. 
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2.9    Laboratory Animal Study 
2.9.1  Animals 
Six Male Wistar-Kyoto control (WKC) rats of 250g were used for the final 
experiment (however other rats were used initially to refine the technique).  
These rats were culled and the hearts dissected out, before being placed in 
calcium free buffer (CFB) solution on ice.  The heart was then delivered to the 
tissue culture laboratory for further processing. 
2.9.2  Tissue slices 
(All tissue processing and media exchanges were performed in a tissue 
culture hood using sterile techniques). 
Once the heart arrived in the tissue culture laboratory the heart and CFB 
solution were poured out into a sterile petri-dish and the dish was placed on ice. 
Initial experiments were performed by dissecting the atria and great vessels from 
the ventricles using forceps and a microtome blade.  The ventricles were then cut 
into smaller longitudinal sections using the same technique.  Unfortunately, this 
proved very challenging and it was difficult to ensure the slices were thin enough 
for culture.   
In an attempt to improve the situation, the sections were fixed in 4% 
agarose.  This was made by heating 4g agarose in 100ml of CFB solution in a 
microwave, then cooling the mixture to 37ºC.  The roughly cut slices were then 
gently transferred onto microtome cassettes and the agarose mixture was poured 
over the top.  These cassettes were then placed in the fridge for 30mins for the    
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agar to set before being cut on a microtome (thickest setting 30µm). 
Unfortunately the tissue was not rigid enough within the agar to obtain accurate 
clean slices and therefore another technique was needed. 
Finally, a rodent heart slicer matrix was purchased (Zivic Instruments, 
Pittsburg, USA) that enabled sections of 500microns to be cut in the coronal 
plane.  First a small volume of CFB solution was poured over the top of the 
matrix to prevent dehydration of the tissue. Then the matrix was placed on a bed 
of ice to cool it.  The heart was then taken out of the CFB solution and placed in 
the matrix using sterile forceps. Prior to sectioning, razor blades (Zivic 
instruments, Pittsburg, USA) were then partially inserted into the slice channels, 
one at a time, such that the blade touched the heart (Figure 2.3). (To remove the 
atria and great vessels the blades were inserted below the atrio-ventricular 
groove.) Once all the channels were filled with blades, the blades were then 
pushed down into the matrix simultaneously.  To obtain the slices, all the blades 
were removed simultaneously between the thumb and ring finger.  Once out of 
the matrix, the uppermost blade was removed to reveal the first slice.  The slice 
was then transposed to the culture well using forceps gently applied to the 
outermost aspect.  This process was repeated until all the slices were removed 
from the blades. 
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Figure 2.3  A Rat Heart Photographed during Slicing, within 
the Heart Slicing Matrix. 
 
 Razor blades are inserted into the slots that are 0.5mm apart. 
    
    84 
Since the slices varied in diameter and thickness of the ventricular walls 
(depending on the level of the section within the ventricle) a weight was taken at 
the end of culture.  Unfortunately this was wet tissue weight because the tissue 
was need for further processing and could therefore not be dried.  The weight of 
the weigh boat was also taken after the slice was removed so that any fluid 
remaining on there was not included in the weight of the slice.  That weight was 
then subtracted from the weight of the slice.    
TGF beta-1, luminescence and MTT colorimeter measurements were 
referenced to these weights. 
2.9.3  Tissue Culture 
Calcium free buffer solution (CFB) was used initially for transfer of the 
heart from animal to tissue culture hood and while sectioning.  Figure 2.4 shows 
the constituents and prepartation methods of the CFB solution. 
The slices were placed in well of media (following sectioning) for incubation. 
The Media used for heart slice culture was taken from the protocol for 
cardiomyocyte culture developed by S.G. Baillie, University of Glasgow.  The 
culture media was made using the protocol below: 
1.  Mix 400ml of DMEM (Invitrogen, Paisley, UK) with 100ml of Media199 
(Invitrogen, Paisley ,UK) 
2.  Remove 75ml of above solution. 
3.  To the remaining 425ml, add 50ml heat inactivated horse serum and 25ml 
of heat inactivated fetal calf serum and 5ml of 1% Penicillin/Streptomycin 
mix.    
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  mM Strength 
Weight(g) per 1 litre 
(1x solution) 
Weight(g) per 500ml  
(10x solution) 
NaCl  120  7.01  35.05 
Hepes  20  4.77  28.85 
KCl   5.4  0.40  2.0 
NaH2 PO4  0.1  0.16  0.78 
Mg SO4 7H2O  0.8  0.20  1.00 
Glucose   5.5  0.99  4.95 
 
 
Figure  2.4    Calcium Free Buffer Solution Recipe 
 
Glucose was added on the day of the experiment. 
NaOH was added (at 37
◦c) to achieve pH 7.4 
The solution was made up in Endotoxin free water and autoclaved prior to use. 
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During the first few experiments each well of a 6 well plate was filled with 
3ml of media; 1.5ml outside and inside the cell culture inserts (0.4µm pore size 
semi-porous membrane, 30mm diameter, Millicell, Cork, Ireland).  The heart 
slices were placed on top of the membrane inside the inserts.  The slices were 
maintained for 48 hours at 37ºc and 95% air/5% CO2.  This section of the 
protocol was further developed after an initial trial to reduce the volume of media 
in each well and consequently increase the proportion of TGF-β produced 
compared to the volume in the media/serum.  Alternative inserts were purchased 
(0.4µm pore size but 12mm diameter; Millicell, Cork, Ireland) to fit a 12 well plate. 
0.4ml media was added to the inside of the insert and 0.6ml outside as per the 
manufacturer’s instructions. 
  Fetal calf serum and horse serum potentially both contain TGF-β and 
other cytokines that could interfere with the interpretation of the TGF-β assay and 
development of fibrosis. Therefore preliminary experiments were carried out to 
determine if this was an essential component of the media for rat heart slice 
culture. Unfortunately the slices without the added serum were subjectively noted 
to be reducing in viability much more quickly than in those with added serum.  
Published successful rat heart slice culture experiments also reported the use of 
fetal calf serum in the media 
[135]. It was therefore deemed essential and the final 
results were adjusted to take into account the amount of TGF-β in the serum that 
was added to the media. 
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2.9.4  Aldosterone Treatment of Slices 
 
A Stock solution of Aldosterone was made up at 10
-3moles/l in the media 
described above.  Each rat provided 6 or more suitable slices for culture. In the 
first 4 rat hearts, 3 slices were cultured in media alone and 3 were cultured with 
media plus aldosterone 10
-6M. (Figure 2.5) Other concentrations of aldosterone 
(10
-4, 10
-7, 10
-11 moles/l) were used for subsequent rat heart slice culture. 
2.9.5  Sodium Concentration in the Media 
First the sodium concentration of media 199 and DMEM were determined 
from the manufacturer’s information.   
Media 199 contained:   26.2mmol/l  NaHCO3     
        117.2mmol/l NaCl 
        1.01mmol/l NaH2PO4   
         
Total Sodium concentration in Media 199  = 144.41mmol/l 
DMEM contained:    44mmol/l NaHCO3 
        109.5mmol/l NaCl 
        0.9mmol/l NaH2PO4 
        0.4mmol/l tyrosine 
        0.04mmol/l phenol red 
        0.99mmol/l pyruvic acid   
          
Total Sodium Concentration in DMEM solution  = 155.83mmol/l    
    88 
In the culture media containing 1 part Media 199 to 4 parts DMEM the 
sodium concentration was calculated to be 153.54mmol/l. The media was diluted 
to a concentration of 143.34mmol/l and 133.14mmol/l by the addition of 
autoclaved, distilled water.  These altered sodium concentrations were used, 
along with aldosterone at 10
-6M, in the experiments using the last two rat hearts.  
In these experiments the slices were cut in half so that for each heart; 3 half 
slices were treated with media alone; 3 halves with aldosterone 10
-6M, 3 halves 
with diluted media sodium and 3 halves with both aldosterone 10
-6M and diluted 
media sodium.   
2.9.6    Obtaining Samples for Tissue Processing and TGFβ-1 
Quantification 
After 24 hours of culture, the 12 well plates were removed from the 
incubator.  The supernatant from each well was aspirated and collected in 
labelled epindorfs.  These were stored at -80
◦c for subsequent analysis. 
The media was replaced in each well and the plate was then incubated for 
a further 24 hours. At the end of the 48 hour incubation the supernatants from 
each well were again aspirated, collected and frozen in epindorfs.  The slices 
were weighed (as previously described) and then cut in half using a razor blade. 
One half was fixed in 10% formaldehyde overnight at 4
◦C and then (1x) PBS at 
4
◦C awaiting tissue processing (Shandon Excelsior, Thermo-scientific, USA). The 
other halves were placed in a reservoir of O.C.T. (a water soluble glycol and 
resin compound) and then snap frozen at -60
◦C using the cryobar in the cryotome  
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Figure 2.5      Diagramatic Representation of the Experimental 
Steps used in the Rat Heart Tissue Culture 
Experiment. 
Contents of each well was 
aspirated, and stored for 
freezing. 
Tissue slices were weighed and 
then cut in half 
This half was fixed in 
formaldehyde, then 
PBS, before being 
tissue processed and 
sectioned 
This half was fixed in 
OCT and snap 
These sections were 
stained with picrosirus 
red or trichrome blue 
media 
media 
media  Aldo 
10
-4 
Aldo 
10
-4 
Aldo 
10
-4 
Contents of 
each well was 
aspirated and 
then 
replaced. 
media 
media 
media  Aldo 
10
-4 
Aldo 
10
-4 
Aldo 
10
-4 
Epindorf filled with 
well contents, 
labelled and frozen 
Following 24hr incubation 
Re-incubate for a 
further 24hrs    
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(Shandon Cryotome, Thermo Scientific, USA).  The cryofrozen samples 
were then transferred to the -80
◦C freezer on dry ice for storage. (Figure 2.5) 
2.9.7    Silination Method for Preparing Histology Slides 
All slides used in this experiment were silinated prior to use to prevent 
slipping of the tissue section on the slide. 
In a fumehood, Container 1 was filled with 7ml APES and diluted with 
350ml Acetone. Container 2 was filled with 300ml acetone and Container 3 and 4 
with distilled water.  Glass Microscope Slides (76x26mm, Menzel-Glaser) were 
placed in a slide rack and immersed in the first container (APES/Acetone) for 5 
seconds.  It was then rinsed in acetone for a few seconds before being immersed 
in Container 3 for 5 mins and then Container 4 for 5 mins. The slides were then 
placed in an oven to dry at 42ºC overnight. 
2.10      Paraffin Sectioning and Staining 
Following PBS immersion the formaldehyde fixed heart slices were placed 
in cassettes and the cassettes labelled.  These were then placed in the tissue 
processor overnight where they were put through a series of washes including 
formalin, alcohol, xylene and finally wax.  Once the processing was complete, the 
cassettes were removed and placed in a 60ºC wax chamber until they were 
ready to imbed.   
Imbedding involved filling a plastic container with hot wax and then placing 
a heart slice in the middle.   The container was then transferred to a cold spot 
allowing the bottom layer of wax to set and the heart slice to be held firmly in    
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position.  The cassette was then placed on top of the slice and wax before 
allowing the wax to set on a cold plate. 
Once the wax had set the plastic container was removed and the block 
was ready to be sectioned on the microtome. The wax block was pared in and 
then the microtome was set to 5 microns.  Sections were delicately cut from each 
heart slice, before transferring them to a water bath at 40ºC.  (The water bath 
was used to remove any wrinkles in the wax and to wash off any debris on the 
sections.)  The sections were then carefully placed on a silinated microscope 
slide. Two-three sections of each tissue slice were cut so that more than one 
stain could be used on each.  
In order that the sections could dry and adhere to the slides, they were 
then placed in an oven at 60ºC for 3 hours and then 40ºC overnight. The 
following morning the slides were removed from the oven and stained, using the 
techniques described below. 
2.10.1    Picrosirus Red Staining  
This stain was used to stain collagen red within the slices, with a co-
staining for nuclei using haematoxylin. Each slide was de-waxed and then 
hydrated with washes of the solutions described below (each for 7 minutes): 
·  Histoclear  
·  100% Ethanol  
·  95% Ethanol  
·  70% Ethanol  
·  Distilled water    
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Next Weigerts haematoxylin (equal measures of Part A and B) was used 
to wash the slides for 8minutes, followed by a wash in running tap water for 
10minutes. 
Following this, the slides were stained with picrosirus red for one hour, 
washed in acidified water (0.86ml of HCL acid in 1 litre of distilled water) for 5 
minutes, twice and then tap water for 5minutes, twice. 
The slides were then vigorously shaken and blotted dry to remove any 
excess moisture. In order that the slides were dehydrated, 3 washes of reducing 
concentrations of ethanol were used for 7 minutes each: 
·  70% Ethanol 
·  95% Ethanol 
·  100% Ethanol 
Then histoclear was used for 1 minute, before mounting the cover slip on each 
slide with histomount. The slides were then viewed under a light microscope to 
assess the amount of fibrosis present. 
2.10.2    Trichrome Staining 
Trichrome stain was used to identify collagen within tissue.  Three dyes 
were used; the first stain (Biebrich Scarlet 1%) binds to cytoplasm, muscle and 
collagen, the second (Phosphotungstic and Phosphomolybdic Acid) allows the 
collagen (but not the cytoplasm) to lose the Biebrich scarlet stain.  The third 
(Aniline Blue) then stains the collagen blue. Each slide was de-waxed and then 
hydrated using a number of washes for 7 minutes each: 
·  Histoclear     
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·  100% Ethanol  
·  95% Ethanol  
·  70% Ethanol  
·  Distilled water 
 
Next the Bouin’s solution was heated to 56ºc in a waterbath. Once the 
slides had finished being de-waxed and rehydrated they were placed in the 
Bouin’s solution for one hour. 
Following this they were washed in running tap water for 10 minutes to 
remove the picric acid (contained within the Bouin’s solution).  Then they were 
placed in Weigert’s working haematoxylin for 10 minutes before being rinsed 
again in distilled water. Next the slides were stained using Biebrich’s Scarlet for 2 
minutes. They were then rinsed in distilled water prior to staining in 
Phophotungstic/phosphomolybdic acid for 10 minutes.  The next stain used was 
Aniline Blue which the slides were placed in for 5 minutes. They were then rinsed 
in distilled water, placed in Acetic acid (1%) for 3 minutes and rinsed again. 
The slides were then dehydrated using two 7 minute washes of 95% ethanol and 
two, 7 minute washes of 100% ethanol.  Finally, the slides were placed in 
histoclear for 1 minute. The slides were then ready for mounting with coverslips; 
using histomount. 
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2.11  TGF Beta-1 Gene Expression - Polymerase Chain 
Reaction (PCR) 
2.11.1   Primers 
·  TGFβ-1 primer (TGF 1) – 20 bases 
Forward – 5’- TGA GTG GCT GTC TTT TGA CG -3’ 
Reverse – 5’- TTC TCT GTG GAG CTG AAG CA -3’ 
This was designed using the program Primer3 (http://www.embnet.sk/cgi-
bin/primer3_www.cgi) and was made from the known sequenced DNA for rat 
TGF beta 1 (Genebank; accession number NM_021578). Product size – 182 
base pairs 
·  TGFβ-1 primer (TGF 2) – 20 bases 
Forward – 5’- TGC TTC AGC TCC ACA GAG AA -3’ 
Reverse – 5’- TGG TTG TAG AGG GCA AGG AC -3’ 
·  Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) – 20 bases 
Forward – 5’- ATG GGA AGC TGG TCA TCA AC -3’ 
Reverse – 5’- GTG GTT CAC ACC CAT CAC AA -3’ 
The above 2 primers were designed by VH Bio, Gateshead, UK. 
2.11.2    Obtaining RNA from Heart Tissue 
Initially spare atrial tissue was used to optimise the PCR conditions. All the 
steps in this method were carried out at room temperature.  First of all the tissue 
was minced roughly with a microtome blade and then sonicated. A tissue    
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homogeniser was used following sonication to further breakdown the tissue. 
Once broken down, 1ml of tri-reagent was added and repeated pipetting was 
used to lyse the cells.  This mixture was then incubated for 5mins. Next 0.2ml of 
chloroform was added and the mixture was shaken vigorously for 15seconds. 
This was incubated for a further 2-3minutes.  Following this the mixture was 
centrifuged at 12,000rpm for 15minutes and the aqueous phase transferred to a 
fresh epindorf tube.  To precipitate the RNA, 0.5ml of propan-2-ol was added to 
the epindorf and incubated for 10mins.  Further centrifugation was then required 
at 12,000rpm for 10mins to collect the RNA pellet from the aqueous solution.  
The supernatant was removed and the pellet washed with 1ml of 70% Ethanol. 
The contents of the epindorf were then vortexed and centrifuged at 7000 rpm for 
5minutes. 
The ethanol was then removed and the pellet left to dry. Once dry, 30µl of 
Rnase free water was added and heated to 55-60ºc for 5minutes to allow the 
RNA to dissolve.  A nanodrop was used to quantify the RNA within the sample.  If 
the solution contained more than 1ng/µl then the mixture was diluted down to 
1µg/µl using R-nase free water. 
2.11.3    First Strand cDNA synthesis 
Moloney-Murine Leukaemia Virus Reverse transcriptase (M-MLV RT) kit 
was used (Invitrogen,Paisley, UK) for cDNA synthesis.  
2µl of each gene specific primer (3 pairs) were used, along with 1µl of 
10mM dNTP mix, 1µl RNA and 6µl R-nase free sterile water was added to an R-
nase free epindorf.  Total reaction volume was 20µl.    
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The mixture was then heated to 65ºc for 5minutes before quickly chilling 
with ice.  The content of the tube was then briefly centrifuged before 4µl of 5x first 
strand buffer, 2µl of 0.1M dithiothreitol (DTT) and 1µl of RNase Out Recombinant 
Ribonuclease Inhibitor (40units/µl) were added. 
This mixture was then mixed gently, prior to heating to 37ºc for 2 minutes. 
Next 1µl (200units) of M-MLV RT was added and mixed by gently pipetting up 
and down.  Then the mixture was incubated at 37ºc for 50mins and then 70ºc for 
15mins to halt the reaction. 
2.11.4    PCR 
Go-Taq Flexi DNA Polymerase kit was used initially (Promega, Madison, 
USA).  Using sterile nuclease free PCR tubes the solutions detailed in the Figure 
2.6, were added at room temperature. Once all the contents of the tube were 
added, the mixture was gently mixed by repeated pipetting and then briefly 
centrifuged.  The tubes were then placed in the thermal cycler (PTC-100 
programmable Thermal Controller, MJ Research Inc, USA). (Figure 2.7) Once 
thermal cycling had finished and the reaction was stored at 4ºC the cycler was 
switched off and the samples removed and stored in the fridge until the PCR gel 
was set up. 
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               Component  Final Volume 
5x Green Go-Taq buffer  5 µl 
dNTP mix (10mM)  0.5 µl 
Reverse Primer   0.75 µl  
Forward Primer   0.75 µl 
Go-Taq enzyme  0.75 µl 
DNA  1 µl 
Nuclease free water  16.25µl (this volume is varied to 
make up total volume) 
Total volume  25 µl 
 
Figure 2.6     Ingredients for PCR of Rat Heart DNA 
 
Step  Temperature 
(ºC) 
Time  Number of 
Cycles 
Initial 
denaturation 
94  5 mins  1 
Denaturation  94  30 secs  30 
Annealing  Variable (50-59)  45 secs  30 
Extension  68  1 min  30 
Soak  4  indefinitely  1 
 
Figure 2.7    Thermal Cycling steps for PCR    
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2.11.5    Optimisation 
To optimise the experiment DNA with and without Reverse Transcriptase 
was used. In addition MgCl2 was added at differing concentrations (2.5mM, 5mM 
and 7.5mM), DMSO (1.25µl) and differing volumes/concentrations of DNA were 
used.  The volume of nuclease free water was calculated in these reactions to 
make the final volume of 25 µl. 
The annealing temperature was also varied to include 50ºC, 56ºC and 
59ºC.  The optimal conditions discovered were an annealing temperature of 59ºC 
and the addition of 2.5mM MgCl2 and 1.25 µl DMSO to the reaction mixture.  
2.11.6    Running a PCR Gel 
The gel was made using 40ml (1x) TAE buffer and adding 0.8g agarose.  
The mixture was then heated in a microwave until fully dissolved. Ethidium 
Bromide 4µl was then added and mixed.  Before the agar set, it was poured into 
a prepared gel tray, the larger bubbles were pushed to the bottom of the gel and 
a comb was inserted at the top end to form wells within the gel. 
This was allowed 20-30minutes to set before the comb was gently 
removed and the gel placed into the electrophoresis bath (filled with just enough 
TAE buffer to cover the wells and gel).   
To load the wells, 15µl of the reaction mix was pipetted into each well 
sequentially.  However the first well was left for the 100kbp DNA ladder and 
loading dye (5 µl of each).    
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Once all the samples had been loaded onto the gel, an electrical current 
was run through the solution at 100volts.   
Electrophoresis was stopped when the fastest moving dye had moved half 
way down the gel or the bands had separated out sufficiently.  The gel was then 
viewed in UV light. 
A photo of the gel was then taken (Fluor-S multi-imager, Bio-Rad, USA) to 
record the results. 
2.11.7    Real-time PCR 
·  DyNAmo SYBR Green qPCR kit (Finnzymes, Espoo, Finland). 
·  PerfeCta SYBR Green Fastmix for iQ (Quanta Biosciences, California, 
USA). 
Instructions for real-time PCR for this enzyme master mix are detailed in Figure 
2.9. Using sterile nuclease free PCR tubes the constituents of Figure 2.8 were 
added at room temperature from the kits provided.  The tubes were then placed 
in a thermal cycler using the steps indicated in Figure 2.9. 
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Component  Final Volume 
Master mix (2x)  10 µl 
Reverse Primer   0.75 µl  
Forward Primer   0.75 µl 
DNA  1 µl 
Nuclease free water  7.5 µl (this volume is varied to make up the 
total volume) 
Total volume  20 µl 
 
Figure 2.8   Ingredients for real time PCR of Rat Heart DNA 
 
Step 
Temperature 
(ºC) 
Time 
Number of 
Cycles 
Initial 
denaturation 
95  15 mins  1 
Denaturation  95  30 secs  35 
Annealing  59  30 secs  35 
Extension  72  15 secs  35 
Soak  4  Indefinite  1 
 
 
Figure 2.9   Thermal Cycling Steps for real time PCR 
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2.11.8    Optimisation of Realtime PCR 
Differing concentrations of MgCl2 (1.5M in buffer - 7.5M), DMSO (0-
1µl/reaction) and DNA (1-5µl) were used.The experiments were repeated using 
mRNA obtained from Rat’s Blood buffy coat because it was thought that white 
blood cells would contain a larger volume of TGF beta 1 mRNA.  However none 
of these alterations to the protocol provided any benefit. 
 
2.12    TGFβ-1 ELISA  
(TGFβ-1 mouse/rat/porcine/canine, Quantikine, R&D systems, Minneapolis) 
Cell culture supernatant was used for TGFβ-1 quantification.  First activation of 
latent TGFβ-1 to immunoreactive TGFβ-1 was achieved by acidification of the 
supernatant with Hydrochloric acid (1N) followed by neutralisation with HEPES 
(0.5M) /Sodium Bicarbonate (0.5M) solution.  After this the samples were 
immediately assayed on the Elisa plate. 
This protocol is taken from the manufacturers guidelines: 
1.  Cell culture supernatant samples were defrosted and all reagents 
brought up to room temp. 
2.  The TGFβ-1 control was reconstituted with 1.0ml of deionised water. 
3.  25ml of wash buffer was added to 600ml of deionised water (to make 
625ml) 
4.  20ml of calibrator diluent RD5-53 was diluted in 60ml of deionised 
water (to make 80ml of 1x solution)    
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5.  TGF standard was reconstituted with 2.0ml of calibrator diluent RD5-53 
(1x). This was mixed and allowed to stand for a minimum of 5 minutes 
with gentle mixing prior to making dilutions 
6.  To 350µl of supernatant 70µl was added of 1N HCL and mixed well 
7.  Then incubated for 10mins at room temp 
8.  The reaction was then neutralised by adding 45.5µl of 1.2N NaOH / 
0.5M HEPES 
9.  Preparation of the standard solutions: 
200µl of the calibrator diluent RD5-53 (1x) was pipetted into a 
polypropylene tube with 200µl of water in it, mixing well. 200µl of that 
reaction was then aspirated and transferred to the next tube with 200µl 
of water in it.  This dilution of 1:1 was completed when 6 tubes were 
filled.  The original calibrator solution (served as a zero standard) and 
the diluent RD5-53 as a high standard.   
10.  Next 50µl of Assay Diluent RD1-21 was added to each well 
11.  Then 50µl of Standard or activated sample was added and repeated in 
triplicate. The plate was then gently tapped for one minute. 
12.  This was incubated for 2hrs at room temp 
13.  Each well was aspirated and washed, repeating the process three 
times using wash buffer (400µl). Complete liquid removal after each 
step is important. After the last wash any remaining buffer was 
removed and the plate inverted before blotting it against clean tissues.    
    103 
14.  Next 100µl of TGF conjugate was added to each well, covered with an 
adhesive strip and incubated for 2 hrs at room temp. 
15.  Equal volumes of the colour reagents A+B were then mixed together 
and used within 15 minutes (protected from light). 
16.  Step 13 was then repeated 
17.  After the final wash cycle, 100µl of substrate solution was added to 
each well and then incubated for 30mins at room temp in the dark.  
18.  Then 100µl of stop solution was added to each well. One the every 
well had stop solution added the plate was gently tapped to ensure 
mixing. 
19.  The optical density of each well was then determined within 30 mins 
using microplate reader set at 450nm. 
20.  A standard curve was calculated from the readings for the different 
standard concentrations. 
21.  The concentration of each sample was calculated from the standard 
curve and then multiplied by the dilution factor 1.3.  All concentrations 
were then referenced to the weight of the slices. 
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2.13    Determination of the Viability of the Incubated 
Ventricular Tissue Slices 
2.13.1    MTT assay 
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide was used 
as a biological marker to detect living cells.  MTT is cleaved only by active 
mitochondrial dehydrogenase enzymes and has been shown in other studies to 
reliably predict cell viability 
[136].   
Tissue slices in media were treated at 0 hrs, 24 hrs and 48hrs of 
incubation with 20µg/ml of MTT. After treatment with MTT, the slices were 
incubated for a further 4 hours at 37ºC and 5% CO2 /95%air, prior to assaying. 
Since the media contained phenol red, and this interfered with the 
wavelength recorded during the assaying process, it was removed after 
incubation was complete.  It was replaced with 1ml of calcium free buffer solution 
and 1ml isopropanol.  The solution was then vortexed for 2 minutes; shaken to 
ensure thorough mixing, and then left to stand for 10 minutes to allow the cleaved 
MTT to dissolve out of the slice.  Once the 10minutes were up, 200µl of the 
solution was added to 3 wells of a 96 well plate.  Another 3 wells were filled with 
100µl of isopropanol and 100µl of CFB as a control. 
A 1420 multilabel counter (Wallac, Victor
2, PerkinElmer Life Sciences, 
USA) was then used to detect wavelengths of 540nm. The absorbance readings 
were referenced to weight of the slice in an attempt to standardise the assay for    
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the size of the slice and therefore give a rough estimate of the number of cells 
assayed. 
2.13.2 Cytotoxicity Luciferase Assay 
Cytotox-Glo Cytotoxicity assay (Promega, Wisconsin, USA) was used to 
detect dead cell protease activity.  Dead cells leak proteases which cleave 
luminogenic AAF-Glo substrate.  Once cleaved, aminoluciferase is released, 
which results in luciferase-mediated production of photons 
[137].  A lysis reagent is 
then added to determine the photon production after 100% cytotoxicity and 
therefore the proportion of initial dead cells in relation to the number in the total 
sample. 
The method described in technical information provided by promega was 
for cell lines and therefore needed to be adapted
 [137]. The un-adapted method is 
detailed below: 
1.  Warm all the assay components in a waterbath at 37ºC 
2.  Add 5ml of Assay buffer to AAF-Glo substrate bottle 
3.  To prepare the lysis reagent; 33µl of digitonin is added to another 5ml of 
Assay buffer.  This is then mixed well. 
4.  Harvest adherent cells, wash in fresh medium and re-suspend in new 
medium (without phenol red indicator) 
5.  Count the number of viable cells using a haemocytometer and trypan blue  
6.  Dilute to desired cell density 
7.  Add 100µl of medium and cells at desired density to each well 
8.  Add 50µl of CytoTox-Glo assay reagent prepared earlier to each well    
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9.  Incubate at room temperature for 15 minutes and then measure 
luminescence 
10. To determine the luminescence if all the cells were lysed; 50µl of lysis 
reagent is then added to each well and incubated for a further 15 minutes 
at room temperature 
11. Luminescence was then re-measured in the same samples 
 
However since this experiment used tissue slices rather than cell lines we 
needed to determine the effectiveness of the assay in our samples.  We tried 
adding collagenase to the slices, to break down the extracellular support 
thereby breaking the slice down to its constituent cells before adding the 
CytoTox-Glo reagent.  The idea behind this was to see if this improved the 
sensitivity of the test and because then we would be able to determine the 
viable cell count in the wells.  Slices were treated with 100µl of collagenase 
type 1 at 400units/ml and then pipetted up and down gently. A 10µl sample of 
this solution was taken and 10µl of trypan blue was added.  A 
haemocytometer was used to detect the number of viable cells after 
collagenisation (i.e. the number that did not turn blue). 20µl of the rest of the 
solution was added to each well to be assayed. 80µl of PBS was added to 
make a total volume of 100µl. 50µl of CytoTox-Glo assay reagent was then 
added and incubated for 15minutes at room temperature. 50µl of lysis reagent 
was added to the same wells. Incubated again for 15 minutes and then 
luminescence read again. Results indicated no significant increase in the    
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signal after 100% lysis indicating that collagenisation probably caused 
considerable lysis in itself.  This was also confirmed using the 
haemocytometer and trypan blue exclusion where most of the cells were non-
viable prior to lysis reagent addition.  Since there was insufficient time to 
further optimise collagenisation of the samples it was decided that we would 
use the previous method without collagenase addition for this experiment. 
Without breaking down the slice in to its constituent cells, we were unable 
to count the number of viable cells prior to the first part of the assying 
process.  It was decided that the slices would be assayed whole and then the 
result would be referenced to the weight of the slice. 
First the slice was washed twice in PBS (to remove any proteases on the 
surface of the cells and to remove any remaining phenol red).  Next, the slice 
was added to 500µl of PBS in an epindorf.  250µl of the Cytotox-Glo assay 
reagent was then added to the epindorf. This was incubated for 15minutes at 
room temperature before 150µl of the reaction was pipetted into 2 wells of a 
96 well plate.   
Then 150µl of lysis reagent was added to the slice and remaining solution 
and again the mixture was incubated for 15minutes at room temperature.  At 
the end of the 15 minutes, 200 µl of reaction mixture was added to 3 new 
wells of the 96 well plate and luminescence read again. Luminescence was 
read using the 1420 multilabel counter (Wallac, Victor
2, PerkinElmer Life 
Sciences, U.S.A.) described in the MTT assay methods.  The protocol was    
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changed though, to read luminescence and to read each well for 5 seconds, 
and then calculate the count per second. 
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Chapter 3:   West of Scotland Kidney Disease 
Study 
3.1   Introduction 
Renal failure markedly increases the risk of cardiovascular disease and in 
particular sudden cardiac death.  Alongside this, it has also been determined that 
cardiovascular disease in renal failure differs from that in the general population.  
The term uraemic cardiomyopathy incorporates three; often distinct, but 
sometimes overlapping pathologies that have been indentified in this group.  
These are left ventricular dilatation, left ventricular hypertrophy and left 
ventricular systolic dysfunction.   
Rat studies have found that aldosterone causes left ventricular 
hypertrophy in the absence of hypertension.  It also causes an increase in 
fibrosis by increasing for example myofibroblasts and collagen production. 
The role of the RAS in human uraemic cardiomyopathy is not fully 
understood.  However, data in the hypertensive population demonstrates an 
association between left ventricular mass index and serum aldosterone levels.  
Further evidence for this link comes from a study of patients with Conn’s disease 
(hyperaldosteronism).  These patients have been found to have a higher 
incidence of left ventricular hypertrophy than other hypertensive groups e.g. 
essential hypertensive and patients with cushings syndrome 
[138].      
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Left ventricular mass index has even been shown to regress with 
spironalactone treatment in early chronic kidney disease patients 
[139]. 
3.2  Aims 
A study performed in the late 1990s investigated electrocardiographic 
abnormalities in uraemic cardiomyopathy 
[128].  Using this database of patients 
with known chronic kidney disease, dialysis treatment and renal transplant 
recipients; our aim was to determine the relationship, if any, between the renin-
angiotensin system and left ventricular hypertrophy, survival or progression to 
renal replacement therapy. Confounding factors for determination of left 
ventricular mass index, rate of renal progression, survival, renin and aldosterone 
levels were also investigated.   
 
3.3   Methods 
3.3.1  Patients 
Patients were recruited from the Western Infirmary Renal Unit in Glasgow 
between 1998-9.  The study design was a cross-sectional study of non-diabetic 
renal disease patients. Patients were identified and then grouped depending on 
their renal function and renal status (i.e. transplant, currently undertaking dialysis 
or chronic kidney disease). The group of patients classified as “chronic kidney 
disease” included patients with near normal renal function to those who were pre-
dialysis.  Sub-groups of Chronic Kidney Disease (CKD) were then formed using    
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quartiles formed from the range of renal function (Quartile 1 having the best renal 
functions) :-  
Quartile 1(Q1) - serum creatinine (Cr) less than120µmol/L 
Quartile 2 (Q2) – serum Cr 120-200µmol/L 
Quartile 3 (Q3) - serum Cr 200-400µmol/L  
Quartile 4 (Q4) – serum Cr greater than 400µmol/L.  
 
Patients within each group were mailed randomly to establish contact and 
then gain consent.  Exclusion criteria included those listed in the chapter 2, in 
addition to the presence of known diabetic nephropathy, overt heart failure and 
coronary heart disease.  By the end of this process 188 CKD (n=47 per quartile), 
55 haemodialysis (HD) and 53 transplant (Tx) patients were recruited.   
3.3.3  Measurements 
On entry into this study all patients underwent echocardiography, clinic 
blood pressure, ECG and height and weight measurement. Venepuncture was 
then performed after 30minutes rest, to obtain blood for haemoglobin, routine 
biochemistry, aldosterone and plasma renin concentration analysis.  Also, a 
questionnaire was completed to gather information about drug and past medical 
history.  All investigations were completed over the course of one day and in 
dialysis patients this was done on a day after their regular dialysis session. 
Unfortunately the time of day that the venepuncture took place was not recorded. 
In October 2008, I revisited this database and obtained follow-up data 
from the electronic renal patient record.  I recorded survival data, recent and mid    
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follow-up creatinine and current renal status (i.e. transplanted, on dialysis).  To 
determine renal progression the latest or last creatinine up to the 10/10/08 was 
recorded or the last creatinine prior to transplantation/dialysis if applicable.  
Glomerular filtration rate (GFR) was then calculated using the Cockcroft-Gault 
formula.  In the event that no creatinine was available prior to transplantation or 
dialysis then an arbitrary figure of 5ml/min GFR was used.  Progression rates 
were then determined prior to renal replacement therapy initiation, death, or the 
latest creatinine in the records. 
Eight patients in the CKD group who started haemodialysis (HD) or who 
were transplanted (Tx) (7 and 1 respectively) within 1 month of the study starting 
were reclassified as HD or Tx respectively in the follow up analysis.  
 
3.3.4  Statistical Methods 
Parametric data was described using the mean (± standard deviation) and 
non-parametric using the median (± inter-quartile range). In order to compare 
outcomes between the six groups, a one-way analysis of variance (ANOVA) 
calculation was used with a Bonferroni correction. P-values are quoted in 
reference to the variance from the 1
st or 2
nd Quartile group of CKD patients. 
Correlations between non-normally distributed data were analysed using 
the Spearman correlation co-efficient. All regression analysis was performed 
using linear regression with an “enter” method for inputting variables. Kaplan-
Meier survival analysis was used to demonstrate any significant differences in 
survival.    
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All statistical analysis was performed using SPSS v15.0 (SPSS Inc., 
Chicago, IL, USA). 
 
3.4   Results 
In the CKD groups, follow-up renal status (i.e. dialysis, transplant, CKD) 
and mortality status was obtained from the electronic patient record.  Status was 
available in all 179 patients however recent creatinine was only available in 167 
patients. 
In the dialysis (HD) group renal status was available for all patients and 
survival status was absent in only 2 patients. 
Information on transplant patients’ death status was missing in 12 patients, 
perhaps due to the fact that very soon after their transplant operation they are 
followed up in satellite clinics without access to our electronic database and also 
due to the increased geographical movement in this group. 
The characteristics of each group are shown in Figure 3.1 and 3.2 below.  
Unfortunately due to the redistribution of 8 CKD patients to the HD and Tx groups 
(as described above) the distribution of patient numbers, sex and age 
demonstrated some significant differences.  In particular the 4
th Quartile of CKD 
had almost half the number of males than the 1
st Quartile.  Patients in the 2
nd-4
th 
Quartile were also significantly older than those in the 1
st quartile. BMI was 
significantly lower in the patients on renal replacement therapy or transplanted. 
The distribution of treated systolic blood pressure was found to be similar in each 
group.      
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The diastolic blood pressure was also similar, except in the case of the Tx 
group who had a significantly lower reading. Haemoglobin was found to fall within 
the groups from Q1 where it was 14g/dl down to 10.9g/dl when they reached 
dialysis. PTH followed a similar trend but as expected it increased as the renal 
dysfunction increased. CRP also increased with renal dysfunction. PTH, CaxPO4 
and CRP reduced in the transplant group compared with Q4 and the HD group.  
Another unsurprising result was the demonstration of significantly more patients 
in Q4 and the HD group who had a history of cardiovascular disease. (Figure 3.1) 
Particularly significant were the differences found in ACEI,ARB and BB 
prescription; CKD patients being prescribed the majority of ACEI/ARBs (35.2% vs 
6.5% HD and 18.5% Tx) and transplant patients the beta-blockers (53.7% vs 
35.8% CKD and 19.4% HD).  (Figure 3.2)  
No statistical significant difference was found when comparing any group 
and the 1
st Quartile in terms of aldosterone, total renin, ARR, renal 
progression/year and 24hr urinary creatinine. (Figure 3.3) 
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Q1  Q2  Q3  Q4  HD  Tx 
Number  47  46  47  39  62  54 
% Male  61.0  58.7  40.4  30.8  59.7  57.4 
Age (yrs) 
40.7 
[10.1] 
49.4* 
[12.4] 
49.1* 
[13.0] 
56.9* 
[12.5] 
46.1 
[14.0] 
41.9 
[12.4] 
BMI 
27.1 
[7.6] 
25.7 
[6.6] 
26.0 
[6.5] 
24.8* 
[6.4] 
23.0* 
[5.6] 
24.4* 
[6.9] 
% Diabetic  2.1  8.7  2.1  5.1  4.8  3.7 
% CVD  4.3  0.0  12.8  23.1**  19.4**  13.0 
SBP 
150.0 
[31.0] 
140.0 
[29.3] 
144.0 
[28.0] 
148.0 
[36.0] 
148.5 
[42.5] 
138.0 
[21.5] 
DBP 
84.0 
[20.0] 
81.0 
[16.5] 
89.0 
[12.0] 
78.0 
[14.0] 
88.5 
[25.3] 
80.0* 
[15.3] 
Hb 
14.1 
[2.6] 
13.4* 
[3.1] 
11.4* 
[1.9] 
11.1* 
[1.5] 
10.9* 
[2.7] 
12.2* 
[2.3] 
CaxPO4 
2.29 
[0.68] 
2.17 
[0.49] 
2.63 
[0.70] 
3.36 
[1.00] 
4.24* 
[1.43] 
2.22* 
[0.75] 
PTH 
3.6 
[2.7] 
5.4 
[4.3] 
12.2 
[16.2] 
31.4* 
[23.6] 
45.6* 
[50.8] 
8.2 
[10.7] 
CRP 
2.2 
[2.2] 
2.7 
[3.3] 
3.2 
[4.7] 
4.0 
[4.6] 
5.3 * 
[11.1] 
1.9 
[2.4] 
Alb 
43.0 
[3.0] 
42.0 
[4.0] 
42.0 
[4.0] 
41.0* 
[3.0] 
41.0* 
[4.5] 
41.0 
[5.0] 
 
Figure 3.1    Group Characteristics in the West of Scotland 
Kidney Disease Study 
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Key:   BMI, body mass index (kg/m
2)  
CVD, history of Cardiovascular disease 
SBP, systolic blood pressure (mmHg) 
DBP, diastolic blood pressure (mmHg) 
Hb, haemoglobin (g/dl) 
CaxPO4, Calcium and phosphate product (mmol/l) 
PTH, parathyroid hormone (pmol/l) 
CRP, C-reactive protein (mg/dl) 
Q1-4, CKD quartiles 1-4;  
Albumin (g/l).  
 
·  p<0.05 for comparisons with Quartile 1; **p<0.05 for comparisons with 
Quartile 2 (ANOVA with bonferroni correction).  
 
·  The interquartile range is quoted in paracentesis. 
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   Q1  Q2  Q3  Q4  HD  Tx 
ACEI/ARB (%) 
17 
(36.2) 
14 
(30.4) 
19 
(40.4) 
13 
(33.3) 
4 * 
(6.5) 
10 
(18.5) 
BB (%) 
9 
(19.1) 
14 
(30.4) 
22 
(46.8) 
19 
(48.7) 
12 
(19.4) 
29 * 
(53.7) 
CCA (%) 
10 
(21.3) 
13 
(28.3) 
13 
(27.7) 
25 * 
(64.1) 
10 
(16.1) 
21 
(38.9) 
Diuretic (%) 
5 
(10.6) 
8 
(17.4) 
15 
(31.9) 
19 * 
(48.7) 
8 
(12.9) 
10 
(18.5) 
 
 
Figure 3.2  Medication at the Time of Enrolment into the Study. 
 
Key:               ACEI, Angiotensin converting enzyme inhibitor 
    ARB, Angiotensin II receptor blocker 
    BB, Beta-blocker 
    CCA, Calcuim channel antagonist 
Diuretic, any diuretic (only 1 patient was taking an aldosterone 
antagonist).  
 
Percentages are recorded in brackets. * p= <0.05 for comparisons with Quartile 1 
(ANOVA with bonferroni correction).     
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   Q1  Q2  Q3  Q4  HD  Tx 
Aldosterone  
16.5 
 [17.7] 
19.0 
[19.5] 
19.5 
[39.0] 
16.5  
[29.8] 
15.5  
[21.0] 
12.0 
[4.5] 
Renin 
17.0  
[20.5] 
19.0 
[34.0] 
13.0 
[31.0] 
10.5 
[39.0] 
12.0 
[33.0] 
27.5 
[38.0] 
ARR 
1.1  
[2.7] 
1.4 
[2.1] 
1.3 
[5.0] 
1.6  
[3.8] 
1.0 
[5.0] 
1.2 
[1.4] 
Rate of prog./yr 
2.4  
[4.4] 
2.1 
[3.6] 
2.8 
[3.9] 
2.2  
[3.1] 
n/a 
 
n/a 
 
24hr Urine Prot  
0.1  
[0.3] 
0.2 
[1.4] 
0.3 
[1.3] 
0.9 
 [1.5] 
1.7 
[4.7] 
0.1 
[0.1] 
 
Figure 3.3      Aldosterone and Renin results, Renal Progression            
Rates and Proteinuria. 
 
Key:   -ARR, Aldosterone renin ratio  
-Rate of prog/yr, rate of reduction in Cockcroft-gault GFR per year 
(ml/min/yr)   
-24hr Urine Prot, 24hr urinary protein (g/24hr) 
-n/a, not available.  
Units:  Aldosterone (ng/dl); plasma renin concentration (ng/l). 
The interquartile range is quoted in paracentesis.    
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Renin results were found to be significantly different depending on the use 
of ACEI (p<0.001) and BB (p=0.002) in the CKD group. However, Aldosterone 
levels were not significantly different when comparing the use of any of the 
groups of medication recorded.  When considering the ARR; beta-blockers use 
was found to be associated with a higher ARR (p<0.001). 
Although no significant differences were identified between the groups in 
terms of the presence of LVH or a reduced ejection fraction, a lower proportion of 
patients in the Tx group had a reduced ejection fraction than the other 5 groups.  
This was despite the persisting high prevalence of left ventricular hypertrophy in 
this group. (Figure 3.4) No significant correlations were found between 
aldosterone, renin or ARR and LVMI in any groups.  However a positive 
correlation was found between systolic blood pressure and LVMI (R= 0.282, 
p=<0.001) and between LVMI and rate of progression of renal dysfunction (R= 
0.224, p=0.005) in all CKD patients. 
3.4.1 Survival Data 
As expected, mortality rates increased with decreasing creatinine 
clearance and in those patients on dialysis. Those patients, who were 
transplanted, were found to have improved survival rates compared to those on 
HD or Quartile 4 CKD. (Figure 3.5)  
We attempted to determine risk factors for death in these groups of 
patients. Neither achievement of blood pressure goals nor the presence of LVH 
had any significant effects on mortality in these patients. Variables that did 
demonstrate a trend towards a significant difference in survival were a CRP of    
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>3.29mg/l in the 3
rd and 4
th quartile (p=0.26) and a 24hour urinary protein level of 
≥1g/day (p=0.023). 1g/day was used as the cut-off level because this level of 
proteinuria has been shown to be associated with a higher rate of renal 
progression and cardiovascular disease.  An ARR of greater than 1.31 (the 
median result) in the CKD population showed a trend towards an increased 
mortality rate although neither renin nor aldosterone levels demonstrated any 
significant effects.   
3.4.2 Correlation with Rate of Renal Progression 
No significant correlations were found between aldosterone, renin, ARR or 
CRP and the rate of renal progression in any groups.  However 24 hour urinary 
protein and BMI were positively correlated with the rate of renal progression (R= 
0.187, p=0.024 and R= 0.167, p=0.032 respectively). 
Linear regression analysis demonstrated a significant predictive value with 
diastolic but not systolic blood pressure (R
2=0.018 p=0.046) for the rate of renal 
progression in the CKD group.  None of the medication groups were found to 
predict renal progression rates including ACEI. 
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  Q1  Q2  Q3  Q4  HD  Tx 
% LVH  86.67  81.82  93.33  87.50  94.74  96.23 
% Patients 
with EF<55% 
65.22  68.89  56.52  66.67  66.67  40.00 
 
 
Figure 3.4   Left ventricular hypertrophy or an Ejection fraction 
  less than 55% Identified from Echocardiogram. 
 
Key:   LVH, left ventricular hypertrophy 
EF, Ejection fraction. 
 
 
 
 
   Quartile of kidney function        
   1  2  3  4  HD  Tx 
No. Dead  0  2  5  11  18  9 
% Dead  0.0  4.3  10.6  28.2  29.0  16.7 
 
Figure 3.5   Table of 10 yr Survival for the West of Scotland 
Kidney Disease Study patients 
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Figure 3.6   A Kaplan-Meier Survival analysis of the CKD 
groups based on aldosterone renin ratio (ARR) 
compared to the median of 1.31ng/dl (p=0.056).    
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Figure 3.7  A Kaplan-Meier Survival Curve comparing the 
mortality rates of patients in the 3
rd and 4
th 
Quartile in the context of a CRP greater than or 
less than the median value of 3.29 mg/l (p=0.26). 
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Figure 3.8  A Kaplan-Meier Survival analysis of all the CKD 
quartiles based on 24hr Urinary Protein results 
of > or <1g/24hrs (p=0.023). 
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Figure 3.9  A Kaplan-Meier analysis of CKD Quartiles 3 and 
4 with respect to the median Haemoglobin level 
of 11.31g/dl (P=0.25). 
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3.4.3  Electrolyte Levels, Blood Pressure and RAS 
ARR was found to be significantly determined by Potassium (K
+) in CKD 
groups (R
2=0.06 p=0.001) however a potential cofounder was the prescription of 
Beta-blockers. 
Given the mechanisms of aldosterone and renin control it was surprising 
that no significant determination of Aldosterone or Renin by Na
+, K
+ or systolic 
blood pressure levels were found. 
 
 
3.5   Discussion 
There has been great interest in the RAS, left ventricular hypertrophy and 
heart failure.  Animal models in particular have demonstrated a link between the 
RAS, cardiac fibrosis and left ventricular hypertrophy.  This interaction has been 
shown in most studies to be independent of blood pressure. 
This dataset describes a selection of patients with a full range of renal 
dysfunction from very mild disease to end-stage renal failure, dialysis patients 
and kidney transplant recipients.  At the onset and first analysis of this dataset 
the number of patients in each quartile of kidney function was equal at 47.  
However, on retrospective analysis, some of the patients in the 4
th quartile were 
started on dialysis or transplanted within a month of being enrolled into the study.   
Those patients were therefore reclassified as dialysis patients or transplant 
patients respectively, from the start of this analysis.  Unfortunately by doing this    
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the distribution of age, sex and BMI became statistically different between the 
different groups. 
Since the blood sampling and analysis was performed before this research 
project, I had no involvement in the initial experimental planning, in particular, the 
aldosterone measurement.  Since we know that aldosterone demonstrates 
diurnal variation and is affected by posture and salt intake it would, in hindsight, 
have been preferable to collect a 24hr urinary aldosterone and salt 
measurement.  That way the average aldosterone level would be measured and 
the effect of the parameters above would have been minimized.  No record was 
made of the time of day the blood sampling occurred so it might have been that 
some patients attended in the morning and some in the afternoon.  These factors 
are thought to account, to some extent, for the lack of correlation between 
aldosterone and the other outcome factors measured. 
Using the follow-up data, neither renin nor aldosterone was found to 
correlate with LVMI or influence survival rates in any group of renal dysfunction.  
However, LVMI, aldosterone and renin levels are also dependent to some extent 
of the medication patients are taking; in particular ACEI/ARB and BB.   A 
significant proportion of patients especially CKD patients were on ACEI (35.2%) 
and BB (35.8%).  ACEI are known to directly target the renin-angiotensin system 
and reduce aldosterone and whereas BB reduce renin directly. These findings 
were confirmed during analysis of this dataset.  Age, sex nor BMI affected renin 
or aldosterone levels.  Information about the length of time patients were taking 
the different medications was not recorded.  This information would have been    
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useful since ACEI have been found in some studies to cause regression of LVH 
and tolerance to ACEI has been described with subsequent increases in 
aldosterone
 [140, 141].  
Only 1 patient in this study was prescribed an aldosterone antagonist and 
no patients were prescribed a renin inhibitor at the time of study in the 1990s.  If 
this study was to be repeated today the proportion of patients on aldosterone 
antagonists and renin inhibitors might well be significantly higher.  These 
medications are also known to alter the hormone levels in the renin-angiotensin 
system and would further confound any results. 
It is interesting to note that the proportion of dialysis patients on ACEI is 
significantly lower than CKD patients despite the fact that there is a higher 
incidence of left ventricular hypertrophy and dysfunction in dialysis patients.  This 
is presumably due to the lack of evidence of mortality or cardiovascular risk 
benefit of ACEI in dialysis patients and the higher risk of hyperkalaemia in this 
group. 
Previous studies have shown improved renal survival and slowing renal 
progression with ACEI especially in addition to ARBs. This was not a finding of 
this study. The reason for this is unclear.  The duration of treatment was not 
classified at the time of study.  Perhaps ACEI/ARBs are prescribed too late to 
slow progression or perhaps the doses of these medications are not high enough 
to affect renal progression.  There is also no reliable way of checking compliance 
to these medications.    
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If this study was used as pilot data for a larger study (as proposed), some 
alterations to the study design or further study prior to starting are suggested.  
The effects of dialysis and transplantation on renin/aldosterone levels are not yet 
fully identified but would be worth studying.  Quantification of the effect of 
ACEI/ARB/BB on renin and aldosterone levels at time points during treatment 
and during dialysis/ transplantation would also be useful. Another possibility is to 
only enroll patients who are not taking any of these medications although this 
would probably select out the more cardiovascular fit patients. 
A measure of proteinuria and natruriesis would also be useful; proteinuria 
has been found to be a risk factor for cardiovascular mortality in this population 
(secondary outcome data) and salt intake has been linked, in animal studies at 
least, to cardiac fibrosis in the presence of aldosterone. 
A relationship between inflammation and survival/cardiovascular disease 
in renal failure has been observed by other researchers.  One of the measures of 
inflammation commonly quoted is CRP and this is one of the most clinically 
relevant and available measurements.  Approximately 30-50% of dialysis patients 
have a raised CRP and the majority the have no identifiable cause 
[142].  The 
raised CRP has shown to be associated with increased mortality and 
cardiovascular disease 
[143, 144].  Our data also supported this link, when the CRP 
was greater than 3.29mg/dl.  
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3.6   Conclusion 
No quartile of renal dysfunction studied, demonstrated any association 
between LVMI/survival rates and random aldosterone/renin levels.  However the 
levels of aldosterone and renin were shown to be affected by ACEI/ARB/BB use. 
Further studies, where patients are not taking these medications and where an 
average 24hr aldosterone level is measured, are recommended before any 
association between the RAS and LVMI/survival can be ruled out.   
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Chapter 4: Aldosterone Study 
4.1 Introduction 
Aldosterone has been found to be a cause of cardiac fibrosis and left 
ventricular hypertrophy independent of blood pressure effects both in vitro and in 
vivo. Recent human study also found a positive correlation between aldosterone 
and left ventricular mass in patients with hypertension 
[145].  Left ventricular 
hypertrophy and the other forms of uraemic cardiomyopathy are well described in 
end stage renal failure.  The recent finding of diffuse late gadolinium 
enhancement 
[133] in this group of patients (indicating cardiac fibrosis) also leads 
us to believe that aldosterone might play a role in it’s pathogenesis. However the 
exact mechanisms for this remain unclear.   
Our aim was to perform a cross-sectional prospective study to investigate 
the relationship between left ventricular hypertrophy (as assessed by cardiac 
magnetic resonance imaging) and aldosterone in dialysis and pre-dialysis 
patients.  
 
4.2 Methods 
4.2.1 Patients 
82 patients were recruited from the Western Infirmary renal unit in 
Glasgow between 2007 and 2009. 35 pre-dialysis and 47 dialysis (including nine,    
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peritoneal dialysis) patients being considered for a renal transplantation were 
enrolled in total. These patients ranged in age from 22 to 78 yrs old.  
We were unable to perform an MRI scan on 8 patients due to 
claustrophobia or ill health. These patients were excluded from further analysis. 
The other inclusion and exclusion criteria for this study can be found in the 
methods chapter. 
4.2.2 Measurements 
Each patient underwent a cardiac MRI scan, blood pressure, exercise 
tolerance test, ECG, venepuncture and height and weight measurement. All 
investigations were completed over the course of one day. 
Venepuncture was performed prior to the MRI scan and samples were 
sent for routine biochemistry and haematology laboratory tests described 
previously.  The remaining blood was centrifuged and frozen at -80ºC within 
20mins of venesection. Serum brain natriuretic peptide (BNP) was measured 
using a one step radioimmunoassay (ShionoRIA, Shinogi, Japan) and serum 
aldosterone levels using the radioimmunoassay (Coat-a-count) described 
previously.   
Patients were interviewed on the day of attendance to determine past 
medical history and current medication.  Details were checked on the electronic 
patient record in areas of uncertainty.    
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4.2.3   CMR and Analysis 
Cardiac MRI was performed using a 1.5 Tesla MRI Scanner (Siemens 
Sonata, Erlangan, Germany).  In the dialysis patients this was performed on a 
post dialysis day to ensure standardisation across the group and to minimise the 
influence of fluid status on our results.  Images were acquired as per the protocol 
described in the methods chapter. 
The duration of the MRI scan was approx. 25 minutes for the mass and 
function images. However, these patients are part of an on-going study and 
therefore image acquisition was also performed for spectroscopy and flow 
mapping.  The results of these latter two techniques are not included in this 
study. 
4.2.4 Statistical Methods 
One patient in the peritoneal dialysis group was found to have a very high 
aldosterone level of 614µg/dl even after repeating the radioimmunoassay.  The 
reason for this result is unclear. The medication of this patient was reviewed but 
they were not on any medication known to have this effect.  Since this extreme 
value was likely to skew the data, values above 120 were grouped together. 
Parametric data (e.g. age, BMI, systolic blood pressure, SBP; diastolic 
blood pressure; DBP) was described using the mean and standard deviation.  
Where the data were non-parametric (e.g. LV measurements, aldosterone) the 
medians and inter-quartile ranges are quoted instead. The standard deviations or    
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inter-quartile range for a given value are recorded in square brackets in the 
following tables. 
Interval data e.g. age, LVMI were compared between two groups of 
patients using the t-test or Mann-Whitney test as appropriate. Values in 
parentheses represent proportions. 
Nominal data e.g. sex was compared between two groups of patients 
using the chi-squared test.   
Correlations between non-normally distributed data were analysed using 
the Spearman correlation co-efficient. 
All regression analysis was performed using linear regression with an 
“enter” method for inputting variables. 
 
4.3 Results 
4.3.1 Baseline Characteristics 
A total of 82 patients were recruited in to the study initially however, after 
exclusions, 33 pre-dialysis and 41 dialysis patients were used for data collection 
and analysis. 
Patient demographics, blood pressure, past medical and smoking history 
and current drug therapy (Angiotensin converting enzyme inhibitors, ACEI; 
Angiotensin II receptor blockers, ARB; Beta blockers, BB; Calcium channel 
antagonists, CCA) are summarised in Figure 4.1.  Distribution of primary renal 
disease between groups is shown in Figure 4.2.    
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Sex, age, BMI and systolic blood pressure (SBP) were similarly distributed 
between the two groups.  Current treatment with an ACEI or diuretics differed 
with a higher proportion of patients in the pre-dialysis groups on both of these 
medications. 
We also compared the numbers of patients with a past medical history of 
macrovascular disease (excluding ischaemic heart disease) and found no 
significant difference between the two groups.  There was a trend towards 
significance for ischaemic heart disease; with a higher proportion in dialysis 
patients. 
The proportions of current smokers were not statistically different either. 
Patients were also analysed by their primary renal disease; no significant 
difference was found between the two groups for any of the categories of primary 
renal disease. 
Aldosterone measurements in both groups were similar (p=0.883). The 
results are outlined in Figure 4.3. 
4.3.2 Cardiac Dimensions and Function 
Patients in both groups had a cardiac MRI scan to determine their LV 
mass and function.  The results are recorded below in Figure 4.4; no significant 
differences were found between the two groups in any of the mass and function 
measurements taken.  Also, no significant difference in the proportions of 
patients defined as having LVH, LV dilatation or a reduced EF when using the 
definitions in the methods chapter (Figure 4.5). 
    
    136 
  Pre-dialysis  Dialysis  P-value 
Number  33  41   
Age (yrs)  54.5 [13.2]  55.4 [12.7]  0.762 
BMI (kg/m
2)  27.1 [4.7]  27.1 [4.8]  0.935 
Male  23 (69.7)  31 (75.6)  0.572 
SBP (mmHg)  148 [22]  145 [22]  0.556 
DBP (mmHg)  82 [13]  88 [11]  0.041 
Current Medication 
ACEI/ARB  21 (63.6)  13 (31.7)  0.005 
BB  13 (39.4)  17 (41.4)  0.858 
Diuretic  16 (48.5)  6 (14.6)  0.002 
CCA  15 (45.5)  18 (43.9)  0.895 
Past Medical History 
IHD  4 (12.1)  12 (29.3)  0.077 
CVA  3 (9.1)  3 (7.3)  0.783 
PVD  6 (18.2)  8 (19.5)  0.885 
CHF  1 (3.0)  3 (7.3)  0.421 
HTN  31 (93.9)  38 (92.7)  0.832 
Smoking History 
Never  16 (48.5)  22 (53.7)   
Current  9 (27.3)  10 (24.4)  0.779 
Ex- smoker  8 (24.2)  9 (22.0)   
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Figure 4.1   Patient Demographics in the Pre-dialysis and 
Dialysis group. 
 
Key:   ACEI, Angiotensin converting enzyme inhibitor 
ARB, Angiotensin II receptor blocker 
BB, Beta blocker 
CCA, Calcium channel antagonist 
IHD, Ishaemic heart disease 
CVA, Cerebrovascular disease 
PVD, Peripheral vascular disease 
CHF, Chronic heart failure 
HTN, Hypertension. 
 
The p-values in bold type indicate the p-values that have reached statistical 
significance.    
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Primary Renal Disease  Pre-dialysis  Dialysis  P-value 
Diabetes  11 (33.3)  8 (19.5)  0.179 
Glomerulonephritis  7 (21.2)  12 (29.3)  0.434 
PCKD  1 (2.9)  4 (9.8)  0.255 
Chr. Pyelonephritis  3 (8.6)  5 (12.2)  0.671 
Renovascular  3 (8.6)  4 (9.8)  0.923 
Unknown/other  8 (24.3)  8 (19.5)  0.626 
 
Figure 4.2    A Table detailing the number (proportion in 
brackets) of each group in terms of their primary 
renal disease. 
 
Key:   PCKD - Polycystic kidney disease 
   Chr. - Chronic 
 
 
 
  Pre-dialysis  Dialysis  P-value 
Aldosterone (ng/dl)  17.8 [16.6]  19.7 [19.6]  0.617 
 
Figure 4.3   Aldosterone results 
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  Pre-dialysis  Dialysis  P-value 
Ejection Fraction (%)  64.4 [15.6]  66.0 [14.3]  0.728 
EDV (ml)  120.9 [49.2]  112.6 [64.2]  0.572 
ESV (ml)  44.9 [22.8]  40.5 [20.7]  0.242 
LV mass (g)  154.0 [90.0]  190.4  [112.4]  0.341 
LVMI (g/m
2)  85.7 [38.7]  96.0 [49.9]  0.364 
EDV/BSA  64.2 [25.0]  57.4 [29.4]  0.358 
ESV/BSA  21.9 [14.3]  19.6 [10.8]  0.190 
 
Figure 4.4    LV mass and Function Measurements 
 
Key:  EDV, End-Diastolic Volume 
  ESV, End-Systolic Volume 
  LV Mass, Left Ventricular Mass 
  LVMI, Left Ventricular Mass Index 
  BSA, Body Surface Area 
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  Pre-dialysis  Dialysis  P-value 
LVH  21 (63.6)  29 (70.7)  0.520 
LV dilatation  1 (3.0)  3 (7.3)  0.421 
Reduced EF   7 (21.2)  9 (22.0)  0.939 
 
Figure 4.5   Proportions of patients with MRI defined LVH, 
LV dilatation or Ejection Fraction <55% 
 
Key:   LVH, Left Ventricular Hypertrophy 
  LV dilatation, Left Ventricular Dilatation 
  EF, Ejection Fraction 
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4.3.3 Correlations  
No significant correlations were found between aldosterone or log 
aldosterone and age, BMI, SBP, DBP, Haemoglobin (Hb), C-reactive protein 
(CRP), Calcium (Ca), phosphate (phos), BNP, troponin, EF, EDV, ESV, LVMI, 
QT dispersal (QTD) or exercise time in the study population as a whole. 
However, Aldosterone was found to be negatively associated with 
potassium (K) levels (correlation co-efficient -0.310, p= 0.009) (Figure 4.6). 
LVMI positively correlated with phosphate (R-square = 0.256, p=0.033 
respectively) (Figure 4.7).  
Despite previous evidence suggesting an association of LVMI with BP and 
QTD we found no correlation between LVMI and these variables. 
4.3.4 Regression Analysis 
None of the variables studied determined the aldosterone levels found in 
these two groups of patients including ACEI, BB, K, SBP and DBP. 
A regression analysis was also performed to determine the factors 
affecting LVMI; Phosphate levels were significant at a p-value of 0.028 however 
Aldosterone levels, ACEI nor BB use were not significant. 
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Figure 4.6   A Graph of Serum Aldosterone plotted against 
Serum Potassium levels.   
 
A Regression line has been applied to the scatterplot. 
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Figure 4.7  A Scatter Graph of Phosphate level (mmol/l) 
against LVMI (g/m
2) 
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4.4   Discussion 
Previous evidence suggests a positive correlation between aldosterone (or 
the aldosterone:renin ratio) and left ventricular mass in hypertensive patients 
[146, 
147]. This study found no significant relationship between aldosterone and left 
ventricular mass in the end-stage renal failure patients studied.  There are many 
possible reasons for this. The fact that the aldosterone was taken as a one off 
serum sample could have been one of these reasons.  Aldosterone is secreted in 
a diurnal pattern and is affected by posture.  Therefore a 24hr aldosterone 
measurement e.g. 24hr urinary aldosterone measurement would have been 
preferable so an average reading could have been measured and these 
confounding factors minimized. 
Another possible explanantion is the interaction between medication and 
aldosterone levels.  In particular, beta-blockers reduce renin production and 
consequently reduce aldosterone production; whilst ACEI inhibit angiotensin II 
release and therefore aldosterone.  Renin levels should also reduce through 
feedback mechanisms.  BB and ACEI were prescribed in a substantial proportion 
of the pre-dialysis and dialysis patients (ACEI 63.6% vs 31.7% and BB 39.4% vs 
41.4%) in this study.  However in this analysis we found no evidence of a 
relationship between aldosterone and any medication recorded. In fact median 
aldosterone was 19.5pmol/dl in both those taking and not taking an ACEI.  
Aldosterone escape has been described following 40 weeks ACEI 
treatment indicating a possible time and patient dependent effect on aldosterone 
production 
[141].  This is in-spite of the proven benefits of ACEI in hypertension    
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[148] and heart failure populations
 [149].  It seems likely given our results that a large 
proportion of patients on ACEI exhibited this escape phenomenon since the 
median aldosterone level in the ACEI treated group was higher than the normal 
range 1-31ng/dl 
[150]. However ACEI use was not associated with aldosterone 
levels in this patient group. It would have been usefult to have a record of the 
duration of treatment with an ACEI however this information was not collected at 
the time.   
Aldosterone has been shown in animal and human studies to be 
associated with end-organ damage. However these effects have mainly been 
demonstrated in the presence of high salt intake. Serum sodium was not found to 
be related to aldosterone levels in this study however the aldosterone and 
sodium measurements were spot random measurements. In future studies we 
suggest determination of salt intake by 24hr urinary sodium measurement, to 
coincide with a 24hr aldosterone measurement, so that the results are not 
confounded by salt intake or postural/diurnal variations in aldosterone. 
Aldosterone to Renin ratio has recently been recognised as the “best 
screening test for the diagnosis of primary aldosteronism” 
[151].  This is because it 
not only indicates the aldosterone level at that moment it also helps to identify 
any problems with feedback mechanisms or inappropriately high levels of 
aldosterone. Unfortunately renin measurement was not performed in this study 
but it would be something to consider including in future studies. 
Rat studies have cited a possible paracrine effect of aldosterone within 
cardiac tissues although this issue is still controversial 
[152]. Therefore, the    
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deleterious effects of aldosterone reported in previous studies, might only be due 
in part to circulating aldosterone (produced in the adrenals).  The remaining 
effects might due to an increase in aldosterone production in cardiac tissue itself.  
For example, evidence post-myocardial infarction has shown an increase in 
cardiac aldosterone levels compared to baseline 
[153]. Also mRNA of enzymes 
involved in aldosterone synthesis has been found in cardiac tissue indicating that 
de-novo synthesis is possible 
[152].  Human studies have failed to confirm this. 
Dialysis patients are subject to extremes of fluid status and potassium 
during the course of their treatment. Therefore you might expect variations in 
aldosterone levels also.  Unfortunately no data exists for the variability of 
aldosterone during ultrafiltration; dialysis or normal values for this subset of 
patients. In this study, we tried to standardise for fluid and potassium status by 
performing venepuncture and the MRI scan on a post-dialysis day. However we 
are aware that this probably didn’t completely eliminate the effect of these two 
parameters on the readings we achieved.  
In patients with normal renal function and consequently therefore, not on 
dialysis, we would expect aldosterone to be regulated to some degree by 
potassium.  That is, when the potassium level falls this blocks further production 
of aldosterone.  However, our results indicate a paradoxical relationship in this 
subset of patients i.e. as the potassium levels fell the aldosterone levels 
increased.  From this result it could be suggested that the regulation of 
aldosterone release differs between end-stage renal failure patients and the    
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general population.  Further investigations of the effects of dialysis on the renin- 
angiotensin- aldosterone system are needed to confirm or refute this hypothesis. 
 
4.5 Conclusion 
Aldosterone was not found to be associated with left ventricular mass 
index in this group of end-stage renal failure patients.  Whether this is a true 
reflection of the interaction between aldosterone and the heart, in the context of 
renal failure, remains unclear.  Further investigations are needed to determine 
the effect of renal replacement therapy, antihypertensive medication and salt 
intake on aldosterone’s effects within the heart.    
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Chapter 5: Rat Heart Slice Study 
5.1   Introduction 
Aldosterone is associated, in animal and select human models, with 
cardiac fibrosis and left ventricular hypertrophy. Angiotensin II has been shown to 
increase TGF-β1; consequently increasing extracellular matrix production and 
decreasing fibrin degradation; two mechanisms which underpin fibrosis and scar 
formation 
[154].  It has now been postulated that TGF-β1 activation may be 
mediated by activation of aldosterone directly rather than angiotensin II’s effect 
on aldosterone. 
Previous researchers have used primary cell culture to perform such 
experiments but usually producing low yields from each animal after a relatively 
long process.  Tissue slice culture could provide an alternative and was used 
widely in the 1940-60s.  
Slice culture has the potential advantage of mimicking the interactions of 
different cells that would normally occur in the heart and maintaining the normal 
architecture.  This method of culturing slices has been shown to be viable (using 
varied techniques e.g. immunohistochemistry, heart beating characteristics, gene 
expression, LDH release and oxygen consumption 
[155-157]). 
Optimal slice thickness has also been evaluated; with a maximum 
thickness of 1mm quoted by W. Habeler et al 
[156] being cultured for up to 3 
months.  However the Walburg formula governing the diffusion of solutes into 
tissue slices indicates that the limiting slice thickness is 0.57mm 
[155].  This    
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corresponds with the findings of Pearson et al, of maximal oxygen consumption 
at 0.5-0.6mm thickness. Most reports have used 0.3-0.5mm thickness with 
success 
[155, 158, 159]. 
Other researchers have used primary rat renal mesangial cells and 
fibroblasts to investigate the effects of aldosterone on TGF-β1 production and 
fibrosis in the kidney 
[160, 161].  However there are few studies investigating 
aldosterone’s effects on TGF beta-1 production in the heart.  The range of 
aldosterone concentrations in this study aimed to include a range likely to invoke 
the maximum response.  No direct comparative studies have been published, 
therefore the results from the previously mentioned renal studies (max effects of 
10
-6 moles/l after 48hours 
[161]) were used as a reference. Physiological 
aldosterone concentrations (0.2 - 8 x 10
-10mol/l) (Coat-a-Count, Siemens, Los 
Angeles) were also included within our range. 
 
5.2   Aims 
The aim was to develop a rat heart tissue slice culture technique which 
could then be used for a pilot study into the effect of aldosterone and salt on the 
production and expression of TGF-β1 and the degree of cardiac fibrosis.  
 
5.3  Materials and Methods 
For the pilot study, six male Wistar-Kyoto control (WKC) rats of 250g aged 
between 12-14weeks were culled and their hearts removed for examination.  The    
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heart was cut into coronal 0.5mm sections from the atrio-ventricular groove down 
the ventricles.  Cutting the heart required the use of the rodent heart matrix 
described in the methods chapter and took place in the presence of cooled 
calcium free buffer solution. 
Once the sections were cut, they were each placed in a well of a 12 well 
plate, on culture plate inserts.  For each rat heart, 3 slices were used as controls 
(labelled “C”) and were placed in a well with 1ml of media only (1M 199:4 DMEM 
and 10% horse serum, 5% fetal bovine serum and 1ml of 1000units Penicillin 
/10mg/mlStreptomycin (Sigma-Aldrich, Dorset, UK)).   
In order to investigate the effect of differing aldosterone concentrations, 
four rat heart were used. Three slices from each heart were placed in wells 
containing either 10
-4 , 10
-6,10
-7 or10
-11 M Aldosterone.  Each of these set of three 
slices were controlled with 3 control slices from the same heart. The slices placed 
in aldosterone were labelled “A” (Figure 5.1) 
To investigate the effect of sodium, 2 rat hearts were used. Three slices 
from each heart were placed in wells containing media diluted to a sodium 
concentration of 143.3mmol/l or 133.1mmol/l.  These wells and the slices within 
them were given the code “N”. Each of the set of three “N” slices were controlled 
with 3 control slices/wells from the same heart. 
It was also possible to investigate the effects of aldosterone 10
-6M in the 
presence of Na concentrations of 143.3mmol/l or 133.1mmol/. For this a further 3 
slices were obtained from each of the rat hearts used for the Na set of the 
experiment. The media was diluted to the two sodium concentrations (detailed    
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above) and then aldosterone was added to a concentration of 10
-6M. These wells 
and the slices within them were given the code “NA” (Figure 5.1) 
Any remaining slices, from the 6 rat hearts, were used to test viability. This 
was done using the MTT and CytoTox-Glo assays described in the Methods 
chapter.  In essence the MTT assay was a colorimetric assay of the activity of 
mitochondrial enzymes within the cells of the heart slice.  The Cyto-Tox Glo 
assay was a luminescence assay that emitted luminescence when it reacted with 
protease enzymes leaked from dead cells within the sample.  This result was 
then compared to that of the luminescence emitted when all the cells in the 
sample were deliberately lysed.  Viable cell luminescence (VCL) was then 
calculated: 
VCL = Post-lysis luminescence – Pre-lysis Luminscence 
 
All slices were incubated for 48 hours at 37ºC and 5% CO2./95%air.  After 
the first 24 hours all the media within the wells were removed and frozen at -80ºC 
for storage.  The media was then replaced with the same concentration of media 
or aldosterone as at the start of the experiment. 
At 48hrs, the slices were removed from the incubator and weighed (mean 
weight 29.8 mcg). The supernatant was removed for storage.  
The slices were then cut in half. Half was formalin fixed overnight and the 
tissue processed for paraffin sectioning. The other half was snap frozen with 
nitrogen, fixed in O.C.T.    
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3 slices in 
Aldo 10-4M 
(A10-4)
3 slices in 
media only 
(C)
1
3 slices in 
Aldo 10-7M 
(A10-7)
3 slices in 
media only 
(C)
3
3 slices in 
Aldo 10-11M 
(A10-11)
3 slices in 
media only 
(C)
4
3 slices in 
Aldo 10-6M 
(A10-6)
3 slices in 
media only 
(C)
2
3 slices in 
media only 
(C)
5
3 slices in Na 
133mmol/l 
(N133)
3 slices in Na 
133mmol/l and 
Aldo 10-6M 
(NA133)
3 slices in 
media only 
(C)
6
3 slices in Na 
143mmol/l 
(N143)
3 slices in Na 
143mmol/l and 
Aldo 10-6M 
(NA143)
 
 
Figure 5.1    Schematic Diagram of the Experimental Method. 
Each slice was incubated for 48hours    
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5.3.1    Staining for Fibrosis 
Two to four, 5 micron sections were cut out of each of the wax embedded 
paraffin blocks prior to oven drying them onto a slide. One of the sections was 
stained with Picrosirus red and the other with Trichrome Blue to look for fibrosis.  
5.3.2    TGF-β1 Analysis 
Preliminary reverse transcriptase polymerase chain reactions were 
undertaken to confirm TGF-β1 gene expression in the rat heart (Figure 5.2).  
However, due to technical difficulties, real-time PCR was unable to quantify TGF-
β1 gene expression.  
TGF-β1 production by the tissue slices were analysed using a rodent TGF-
β1 Elisa kit (Quantikine, R&D systems, Minneapolis).  Each of the frozen 
supernatant samples extracted at 24 and 48hours into the experiment were used 
for analysis.  The samples were thawed once and the TGF-β1 within each 
activated by acidification and then neutralisation (as per the manufacturer’s 
guidelines). 
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Figure 5.2  PCR of Rat Atrial Tissue using GoTaq DNA 
Polymerase Enzyme with addition of MgCl2 
0.25mM and 1.25 l of DMSO to the Mastermix 
 
Key:  T1, TGF-β1 primer 1 
T2, TGF-β1 primer 2 
G, GAPDH primer. 
 * indicates the band produced by the amplification product of the TGF-β1 primer 
1 combining with the TGF-β1 1 mRNA in the cardiac tissue.   
 
A 100bp ladder was used to confirm the size of the amplification product and this 
is shown on the left handside. 
500bp 
T1  T1  T2  T2  G  G 
*    
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5.4      Results 
5.4.1      Viability of Tissue Slices 
5.4.1.1  CytoTox-Glo Results 
CytoTox Glo assay pre-lysis results represented the luminescence 
produced by the protease enzymes (released by dead cells) within the slice at 
the end of the 48hr incubation. The post-lysis results were recorded after a lysis 
reagent was added to the slice.  The difference between these results was 
termed viable cell luminescence.   
The results of this assay are shown in Figure 5.3, 5.4 and 5.5.  These 
results show that there was a reduction in viable cell luminescence (VCL) over 
time even when corrected for the weight of the slice examined.  The percentage 
reduction in VCL from the start of the experiment ranged from approximately 5 – 
47% and was not affected by aldosterone or sodium concentrations. 
5.4.1.2   MTT Assay Results 
The MTT assay was a measure of the mitochondrial enzyme activity within 
living cells.  The results are shown in figure 5.6 and 5.7.  These results show that 
there was a reduction in absorbance detected over time.  However the results 
suggest that there is partial improvement in mitochondrial activity between the 
24
th hour and the 48
th hour of the experiment.   
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Figure 5.3   CytoTox Glo Assay Results for Control Tissue 
Slices (C) at Specified Time Points During 
Incubation. 
 
This graph demonstrates a reduction in viable cell luminescence (an indicator of 
cell viability within the slices) over the 48hour incubation period.  However it also 
shows that a proportion of cells remain viable even at the end of the 48hours. 
 
Key:   (n) - Number of hours of incubation prior to assaying 
  Suffix 
A/B – denotes that the two different results are from two halves of the 
  same  slice of tissue 
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Figure 5.4    CytoTox Glo Assay Results for Aldosterone  
      10
-6M Treated Slices (A) Over a 48hr Period 
 
This graph demonstrates a reduction in viable cell luminescence (an indicator of 
cell viability within the slices) over the 48hour incubation period in those slices 
treated with aldosterone 10
-6M.  However these results are not significantly 
different to the decline in viability in control slices cultured for 48hrs. 
 
Key:  (n)- Number of hours of incubation prior to assaying 
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Figure 5.5   Cyto-Tox Glo Assay Results for Tissue Slices  
      Incubated in Diluted Media (i.e Na 133.3mmol/l) 
 
This graph demonstrates a reduction in viable cell luminescence (an indicator of 
cell viability within the slices) over the 48hour incubation period in those slices 
treated with aldosterone 10
-6M.  However these results are not significantly 
different to the decline in viability in control slices cultured for 48hrs. 
 
Key:  (n)- Number of hours of incubation prior to assaying 
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Figure 5.6   The MTT Assay Viability Results for Control  
      Samples (C). 
This graph demonstrates the mitochondrial activity levels within viable cells at the 
time of assaying.  The results show that after an initial decline in enzymatic 
activity at 24hours this then improved after 48hours. 
 
Key:   (n)- Number of hours of incubation prior to assaying 
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Figure 5.7    MTT Viability Assay Results for Aldosterone  
      10
-6M Incubated Slices (A) Over 48hrs. 
 
This graph shows that the viable cell mitochondrial activity in slices treated with 
aldosterone 10
-6M follows the same pattern as that of control slices shown in the 
previous graph. 
 
 
Key:   (n)- Number of hours of incubation prior to assaying 
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5.4.2   Fibrosis 
As expected perivascular staining was seen with both trichrome and 
picrosirus staining due to the collagen present in the vessel walls.  There was no 
increase in perivascular or any other area of staining for either picro-sirus red or 
trichrome stain under any of the media conditions investigated or over time. 
Some typical examples of the histology staining are shown in Figures 5.8 for 
picro sirus red and Figures 5.9 for trichrome staining.    
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Figure 5.8    Picro-Sirus Red Stained Sections of the Rat  
    Heart Slices incubated in different aldosterone  
    and sodium concentrations in the media.     
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Apart from the first row of pictures the remaining pictures were taken of slices 
incubated for 48hours in the media. The zero hour labelled pictures were of heart 
slices prior to incubation. 
 
Picrosirus stain was used to stain collagen pink. 
 
The scale is shown on the bottom right corner of the image. 
 
Key for all parts of Figure 5.8:   
A – indicates the normal appearances of perivascular collagen staining 
with picrosirus red.   
Control – heart slice incubated in media alone 
Aldo 10
-n – heart slice incubated in the concentration of aldosterone 
shown in mol/l 
Na 133/143 – heart slice incubated in the concentration of sodium stated 
  e.g. 133mmol/l or 143mmol/l 
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Figure 5.8   Picro sirus red stained heart sections in 
different concentrations of aldosterone and 
sodium in the media    
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Figure 5.8  Picro sirus red stained heart sections incubated 
in different concentrations of aldosterone and 
sodium in the media     
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Figure 5.9   Masson’s Trichrome stained sections of Rat 
Heart Tissue in the different concentrations of 
aldosterone and sodium in the media.    
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Apart from the first row of pictures the remaining pictures were taken of slices 
incubated for 48hours in the media. The zero hour labelled pictures were of heart 
slices prior to incubation. 
 
Trichrome stain was used to stain collagen blue. 
 
The scale is shown on the bottom right corner of the image. 
 
Key for all parts of Figure 5.9:   
A – indicates the normal appearances of perivascular collagen staining 
with picrosirus red.   
Control – heart slice incubated in media alone 
Aldo 10
-n – heart slice incubated in the concentration of aldosterone 
shown in mol/l 
Na 133/143 – heart slice incubated in the concentration of sodium stated 
  e.g. 133mmol/l or 143mmol/l 
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Figure 5.9   Masson’s Trichrome stained sections of Rat 
Heart Tissue     
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Figure 5.9   Masson’s Trichrome Stained Sections of rat 
heart sections 
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5.4.3 TGF-β1 Results 
TGF-β1 was found in significant amounts in the media after the addition of 
horse and calf serum (mean concentration = 1056.06pg/ml with a standard 
deviation of 148.88pg/ml).  Unfortunately the serum was vital to the viability of the 
tissue slices and therefore could not be removed from the media prior to analysis. 
Elisa results demonstrated no significant change in TGF-β1 concentration in any 
group from the baseline (i.e. the TGF-β1 concentration in the media).  All results 
were distributed within the variability of the ELISA kit, with only a relatively small 
difference in TGF-β1 from the mean media concentration.  These results are 
shown in Figures 5.10 and Figure 5.11. 
Although PCR was not able to be optimised in time for completion of this 
project we were able to demonstrate that TGF-β1 was being produced by the rat 
heart tissue.  The results of the PCR are shown in methods section. 
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Figure 5.10  TGF-β1 Elisa Results for Control Slices and  
      those Incubated with different concentrations of 
      Aldosterone. 
The Elisa results in the table above are corrected for the media TGF- β1 
concentration and for the weight of the slices cultured (in mcg).  However the 
mean media TGF- β1 concentration is 1061pg/ml, standard deviation 148.8pg/ml. 
Therefore all of the above results are within the error of the Elisa assay. 
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Figure 5.11  TGF- β1 Elisa Results for those slices incubated  
      in Diluted Media (i.e. Na 133.1mmol/l or    
      143.3mmol/l) 
 
 
 
The Elisa results in the table above are corrected for the media TGF- β1 
concentration and for the weight of the slices cultured (in mcg).  However the 
mean media concentration was 1061 pg/ml with a standard deviation of 
148.8pg/ml. Therefore all of the above results are within the error of the Elisa 
assay.    
    173 
5.5     Discussion 
5.5.1   Limitations of the Study 
  Rat slice culture was an experimental technique attempted to try to mimic 
in-vivo tissue structure and cell to cell interactions.  However as this was an 
experimental technique refinement was carried out prior to the investigation of 
the effect of aldosterone/salt on the heart slices.   
The use of the rodent heart matrix allowed reassurance that the thickness 
of the ventricular slices remained relatively constant. However, the diameter of 
the slices varied depending on the distance from the atrio-ventricular groove, 
because the ventricle is narrower at the apex than the base.  It is not known 
whether the diameter of the heart slice also influenced the diffusion of nutrients 
etc. to and from the media into the slice.  
This study demonstrated no significant TGF-β1 production or excretion by 
the heart tissue over 48 hours.  However, if the amounts produced were very 
small then any production could have been overshadowed by the large amounts 
of TGF-β1 in the serum containing media. Attempts were made to try the 
experiment without the use of horse and fetal calf serum however the viability of 
the slices meant this was not possible. 
Within the TGF ELISA results there was variation in TGF-β1 
concentrations detected.  However this variation occurred within the control slices 
and within the media (containing serum) itself suggesting that this variation was    
    174 
within the range of sensitivity of the ELISA itself rather than a true variation in 
production.  
It is also reasonable to suggest that the duration of culture was too short to 
detect any significant fibrosis or TGF-β1 production.  The duration of incubation 
was chosen for viability reasons and because other researchers had obtained 
results after 48 hours in renal cells.  
The viability assessments used in this experiment were essentially 
untested on tissue slices and so adaptation of the techniques used for cell culture 
viability was needed to take account of this. Viability measurements were 
therefore difficult to interpret and optimise.  It is reasonable to think that the 
diffusion of substrate into each cell would be affected by the surrounding cells 
and extracellular structures.  Although the slices were a constant thickness and 
the results were referenced to the weight of the slice, these factors were not fully 
resolved within the time of this project. 
5.5.2   Significance and Context of the Results 
TGF-β1 is a member of a super-family of cytokines called the transforming 
growth factor family; as such it is known to be involved in cell growth and repair.  
But the exact mechanisms and pathways for this are complex and incompletely 
understood.   
Information about TGF-β1’s role in cardiac tissue is limited but expanding. 
For example, it is known to be produced in certain cells within the heart including 
myocytes, lymphocytes and fibroblasts.  Involvement of the Smad pathway has 
been sited most often in the role of TGF-β in cardiac fibrosis. But the    
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concentrations of TGF produced are very small (2.22 ± 0.14ng/mg protein) and 
vary considerably over time and within the same species 
[126]. 
Angiotensin II is a proposed stimulus of release and over-expression of 
TGF-β1 
[162].  Chronic over expression of TGF-β1 has been found to increase 
extracellular matrix production, cause cardiac fibrosis and subsequently lead to 
heart failure
 [154].  In the context of an acute ischaemic insult to the heart, TGF-β1 
is also up-regulated.  Studies show that at the area of insult the levels of TGF- β1 
rise 3-4 fold 
[163].  It is for these reasons that TGF-β1 has become the focus of 
research in an attempt to prevent cardiac fibrosis and subsequent heart failure. 
In this experiment, we were interested in the potential role of aldosterone 
and sodium in the release of TGF-β1 and any subsequent fibrosis that occurred.  
Aldosterone in the context of high salt intake in rats has been shown to be 
associated with left ventricular hypertrophy and cardiac fibrosis 
[67].  It has also 
been suggested that aldosterone, either directly or by induction of angiotensin II, 
stimulates TGF-β1 production and release.  Corroboration of these finding has 
occurred in translational human studies.  These have shown that blockage of 
mineralocorticoid receptors with spironolactone can reduce morbidity and 
mortality in patients with moderate to severe heart failure 
[76].  More recently 
Eplenerone (a selective aldosterone blocker) has been licensed for use in the 
U.K. This has also been shown (in a randomised controlled trial) to reduce 
mortality and hospitalisation rates in patients following an acute myocardial 
infarction who subsequently develop heart failure
 [77].      
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Of the 3 forms of TGF-β it is thought that TGF-β1 is most influential in the 
heart and this is where most research has centred so far.  Perivascular and 
interstitial fibrosis were found to be the consequence of aldosterone and high salt 
intake over an 8 week period in the rats studied by Brilla and Weber in 1992 
[67].  
However, an increase in fibrosis was not seen on histological staining in either 
the aldosterone, high salt or aldosterone and high salt groups in our study.  Some 
of the potential reasons for this are discussed in the limitations section.  The 
48hour duration of the experiment could have been too short for fibrosis to 
develop.  Unfortunately it was not viable to increase the experiment duration 
much beyond 48hours.  
At the time of designing this experiment, 48 hours was chosen for viability 
reasons and had been shown in other investigations to be long enough to elicit a 
response in TGF-β production (albeit in renal glomerula cells) 
[160].  It was also 
thought that a TGF-β1 rise was likely to precede any fibrosis detected 
[104, 121].  
However our research found no significant increase in TGF-β1 production by the 
ventricular tissue over time or due to aldosterone (10
-4 -10
-11M)/salt (133-
153mmol/l) changes within the media.   
The limitations of serum in the media are discussed in section 2.9.3 and 
therefore will not be repeated here.  Other potential reasons not detecting a 
significant result include; TGF-β2 or TGF-β3 having more of a role within the heart 
than previously recognised; the time limit on the experiment was too short to 
invoke the TGF response or that the conditions within the experiment were not a    
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stimulus for a TGF-β1 response at any time.  The number of viable cells within 
the tissue slice would also have implications on TGF-β1 release. 
Tissue slice culture is a technique that enjoys the potential benefits of 
retention of in vivo architecture.  The theoretical advantages of this include intact 
cell to cell interactions, spacial relationships between cell types and   prevention 
of disruption of cytokine pathways and hormone responses. Researchers 
studying cardiac tissue have used many different techniques to maintain the 
slices in culture; some more successful than others.  One of the most successful 
maintained the slices for 3 months 
[156].   Our study showed that the proportion of 
viable cells within the tissue slices dropped steeply over the first 24hours and 
then there was a trend towards a slight increase in the second 48hours.   
However, the techniques used for assessing the viability need to be 
interpreted with caution.  Validation of results within the tissue slices was difficult 
because most research/manufacturers instructions were directed towards 
primary cell culture rather that tissue slices.  It is possible that the tissue slices 
were more viable than shown, and that the permeability of the cell wall for MTT or 
the release and maintenance of the dead cell proteases in the media were 
reduced after time in the media.  It is also possible that the dead cell proteases 
were held within the structure of the tissue slice rather than being released in to 
the media and therefore were not present for assaying.  The subjective 
impression of the slices was of reduced viability over the 48hours of incubation. 
Potential reasons for the presumed reduction in viability could be due to 
the media used.  The media chosen was that used by another group within the    
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University of Glasgow, to culture cardiac myocytes and therefore probably 
favoured viability of this group of cells over others.  Also the rats we used were 
older than the embryonic tissue other researchers used.  However those rats 
were chosen to demonstrate effects in adult rats, ensure enough tissue was 
obtained form each rat for control slices and viability slices to be taken and to 
keep the project within budget.  
Heart tissue is highly oxygenated in the body by the rich blood supply. 
Some other researchers oxygenated the tissue during incubation which could 
provide additional benefits and improve viability if this project was to be repeated 
and improved in the future.   
Further analysis of the media used, revealed a very high glucose 
concentration; 4500mg/l of D-glucose in DMEM and 1000mg/l of D-glucose in the 
Media 199.  This equates to 55.6mmol/l in M199 and 250mmol/l in the DMEM. 
After dilution with the fetal calf, horse serum and pen/strep, the final glucose 
concentration was 177.7mmol/l. Since the human normal glucose range is 
approximately 4-11mmol/l this is a very high concentration and might account for 
some of the reduced viability demonstrated in the heart slices over time.  
However, most neat cell culture media have a glucose concentration between 
1000-2000mg/dl. 
 
5.6   Conclusions 
Neither aldosterone nor changes in salt concentration within the media 
were shown to significantly affect TGF-β1 production/release or the amount of    
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fibrosis within adult rat ventricular tissue slices over a 48hour incubation period.  
However, the limitations of this tissue slice culture technique were difficult to 
overcome in many cases.  The viability of the slices was a particular issue, since 
this restricted the duration of the experiment and reduced the number of cells 
within the tissue that could have been producing the TGF-β1 and collagen. 
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Chapter 6:   Generic Discussion 
The research, detailed in this thesis, aimed to address the title 
“Aldosterone and the Cardiovascular Complications of Chronic Kidney Disease”.  
Aldosterone has held much promise as a potential target for treatment of heart 
failure, blood pressure and the cardiac complications seen in chronic renal failure 
(e.g. cardiac fibrosis and left ventricular hypertrophy).  However the exact link 
between aldosterone and these pathologies is not yet fully understood.  
  Although evidence exists in animals and some patient groups (e.g. 
essential hypertensive patients), confirming a link between aldosterone and 
cardiac complications, the evidence in renal dysfunction is more limited.  
A potential reason for this is the difficultly interpreting data in the context of 
renal replacement therapy, where there are marked fluctuations in fluid 
status/electrolyte balance, as well this many patients are prescribed medications 
that are known to affect the renin-angiotensin system e.g. ACE inhibitors (ACEI) 
and beta-blockers (BB). Greater than 30% of patients in the CKD quartiles of the 
WSKDS were prescribed an ACEI and 18.5% of those on dialysis.  A high 
percentage of patients were also prescribed BB (>45% of CKD quartiles 3 and 4 
and >50% of dialysis patients).  
The normal values quoted for aldosterone and renin are also liable to 
interpretation errors. The normal values are based on patients with normal renal 
function and have not been verified in renal impairment. Given the swings of 
sodium and water concentration in the intravascular space, particularly of dialysis    
    181 
patients, it would be reasonable to suggest that the normal value of these 
hormones would vary considerably.   Furthermore Aldosterone and Renin are 
affected by posture, salt intake and aldosterone has a diurnal secretion pattern. 
Therefore, future investigators would be wise to measure 24hr urinary 
aldosterone and salt to allow for these confounding factors.  
In the West of Scotland Kidney Disease Study, we showed that ACEI and 
BB had significant effect on renin levels.  However, despite our expectations, 
neither ACEI nor BB significantly affected aldosterone levels in the patients 
studied.  
  No significant association was found between aldosterone and any cardiac 
complication in either of the clinical studies undertaken during this research.  
However, further research is needed to address the issues raised above, before 
we can exclude aldosterone as a factor in the development of uraemic 
cardiomyopathy. 
Survival data in the WSKDS also failed to demonstrate a significant 
increase in the risk of death from raised serum aldosterone or renin levels (above 
the median) in the presence of renal dysfunction.  However, the small number of 
patients enrolled in the study meant that the power of this study was not sufficient 
to demonstrate significance, particularly within the different renal function groups, 
and therefore research involving larger patient groups is suggested. 
Very little research had been conducted on aldosterone’s effect on cardiac 
fibrosis in rats, or on TGF-β1 production/release at the time of experimental 
design.  This posed challenges in terms of the range of aldosterone to use, the    
    182 
duration of incubation and the amount of TGF-β1 that we were trying to detect.  
Along with this, and more important to the hypothesis of this technique as an 
experimental model, was the viability of the slices over time.  Again this was 
difficult to interpret in the context of tissue slices rather than cell culture; on which 
the viability tests had been validated. However, our results indicate that the cells 
within the slices did retain some viability at the end of the 48hr incubation but 
these results were very variable. 
  If more time was available for this research project I would have altered 
the media constituents to lower the intial sodium concentration.  The initial 
sodium concentration used was >150mmol/l which is higher than normal in 
serum.  It would have been more scientifically sound, to add sodium to the media 
instead of trying to dilute it as was the case in this experiment (thereby diluting 
more than just the sodium concentration).  The effect of the glucose 
concentration in the media and its effect on osmolality is also a factor to worth 
reassessing in future experiments.   
In conclusion, the human studies performed for this thesis provide useful 
information for future researchers investigating aldosterone/renin effects in renal 
patients.  Unfortunately, the research was inconclusive and therefore further 
research is needed to confirm or refute the link between aldosterone and the 
cardiovascular complications of renal failure in humans. The results of the animal 
study were also inconclusive however important information was gained about 
this experimental technique and valuable lessons learned about potential 
modifications to improve the technique in the future.    
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